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AEP       Asparaginyl endopeptidase 
APS      Ammonium persulphate  
AR       Androgen receptor 
bp      Base pairs 
BSA      Bovine serum albumin 
cDNA      Complementary DNA 
CHAPS     3- ((3-Cholamidopropyl)dimethylammonio)-1- 
       propanesulfonic acid 
CMV       Cytomegalo virus 
CP      Cysteine protease 
CPI      Cysteine protease inhibitor 
dH2O      Destillated water 
DMEM      Dulbecco’s Modified Eagles Medium 
DTT      Dithiotreitol 
DNA      Deoxyribonucleic acid 
E64 Trans-epoxysuccinyl-L-leukylamido (4-
guanidino) butan 
FBS      Fetal bovine serum 
ECL      Enhanced chemiluminescence 
HBr      Hydrobromide acid 
HEK      Human embryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid 
HS Horse serum 
HSV Herpes simplex virus 
IU      Inhibitory units 
kb      kilo bases  
kDa      kilo Daltons 
Ki      Inhibition constant 
LAF      Laminar air flow 
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Leu-Leu-OMe     L-leucyl-L-leucine methyl ester 
MHC      Major histo-compatability complex 
mRNA     Messenger RNA 
MMP      Matrix metalloproteinase 
NH2Mec     7-amino-4-metylcumarin 
NSCLC      Non small cell lung cancer 
OIP       Osteoclast inhibitory peptide 
PA      Poly adenylation signal 
PBS      Phosphate buffered saline 
PDT       Photodynamic therapy 
PMA      Phorbol-12-myristate-13-acetate 
RNA      Ribonucleic acid 
rpm      revolutions per minute 
RPMI      Roswell Park Memorial Institute medium 
RUH-HF     Rikshospitalet University Hospital HF 
SDS      Sodium dodecylsulphate 
SV      Simian virus 
TAM       Tumour associated macrophage 
TBE      Tris-borate EDTA 
TCA      Trichloroacetic acid 
TEMED     N,N,N,N-tetra-methyl-ethylenediamine 
TGF-β      Tumour growth factor-β 
Tris      Tris(hydroxymethyl)aminomethan 
T-TBS                Tris-buffered saline containing 0.05 % Tween 20 
TPI      Thiol-protease inhibitor 
uPA      Urokinase plasminogen activator 








HEK 293 cells were transfected with LGMN-plasmid encoding rat legumain, to establish a 
cell line transiently and/or stably expressing legumain. In addition, HEK 293 cells and a 
number of melanoma cell lines (from Rikshospitalet University Hospital HF) were 
successfully transfected with CST6-plasmid encoding human cystatin M, a potent secreted 
endogenous inhibitor of legumain and other cysteine proteases. Successful CST6-
transfection was evaluated as increase in total inhibitory activity (IU/ml) against papain as 
the target enzyme in media from transfected cells versus control cells (using empty vector; 
pTracer). The increase in total inhibitory activity was much higher in media from the CST6-
transfected HEK 293 cells than the CST6-transfected melanoma cells. In addition, legumain 
activity was measured in cell lysates from CST6-transfected cells, showing decreased activity 
compared to control cells. The legumain activity was nearly abolished in cell lysates from 
CST6-transfected HEK 293 cells and moderately decreased (10-41 %) in CST6-transfected 
melanoma cells. Interestingly, decrease in legumain activity was strongly correlated to the 
potency of total inhibitory activity in media from the same cells. Despite many adjustments 
made to optimize transfection efficacy of HEK 293 cells with the LGMN-plasmid, legumain 
could not be over-expressed. 
Cystatin M-conditioned media from CST6-transfected cells were used to treat living HEK 
293, THP-1 and PC12 cells to investigate how this affected legumain activity in the cells. 
Legumain activity was only moderately decreased in cell lysates of HEK 293 cells treated 
with cystatin M-conditioned compared to control cell media. However, no regulation of 
legumain activity was observed in either THP-1 or PC12 cells after treatment with cystatin 
M-conditioned media. 
Cell lysates from HEK 293, THP-1 and PC12 cells were subjected to size exclusion 
chromatography in an attempt to characterize the molecular weight of active legumain in 
these cells. Surprisingly, different molecular weights were found to be responsible for 
legumain activity in the different cell lines.  Addition of cystatin M-conditioned media to 
HEK 293, THP-1 and PC12 cell fractions of highest legumain activity resulted in inhibition 
of legumain activity. Legumain activity in HEK 293 and PC12 cells was almost completely 
suppressed, but surprisingly only partially inhibited in THP-1 cells. Adding of the cathepsin-
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inhibitors E64 and CA074 to the highest legumain activity fractions from the same cell lines 
resulted in no inhibition of legumain in HEK 293 and PC12 cell lysate fractions. On the 
contrary, the legumain activity was greatly decreased in the THP-1 cell fraction by both E64 
and CA074. This is the first observation of legumain inhibition by E64 and CA074 in any 
cell type. This might indicate an uncharacterized form of legumain or a legumain-like 
enzyme in monocytes/macrophages. 
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1.  Introduction 
 
1.1  Proteases and cancer 
Proteases (or peptidases) have been associated with many aspects of cancer pathophysiology 
[1-4]. Invasive tumour cells and their microenvironments are enriched with a number of 
proteases. Proteolysis plays a crucial role during the process of invasion and, consequently, 
metastasis of tumour cells via cleavage of important proteins involved in cell-cell adherence 
and extracellular matrix [2]. Additionally, protease activity facilitates activation of other 
proteases and the entrance of migrating tumour cells into circulation. Thus by further 
degradation of extracellular matrix components, proteases stimulate tumour growth, invasion 
and angiogenesis through liberation of embedded growth factors in the surrounding matrix 
[2].  In support of previously mentioned findings, an inhibitor of matrix metalloproteinase 
(MMP), Batimastat®, has been shown to cause decreased migration and invasion of tumours 
when applied to a number of tumour cell lines [5]. In addition, examining low molecular 
weight inhibitors of MMP and urokinase plasminogen activator (uPA) led to the conclusion 
that inhibiting proteases had a tumour suppressing and anti-metastatic effect [6].  
1.1.1 Cysteine proteases 
Proteases are enzymes that catalyze breakdown of proteins by cleaving peptide bonds upon 
nucleophilic attack on the carbonyl bond [7]. The cleavage of protein substrates takes place 
either from the N- or C- terminal end of the protein (exopeptidases), and/or in the middle of 
the target protein (endopeptidases). In general, five major types of proteases have been 
identified (cysteine, serine, threonine, aspartate, and metalloproteinases) [8]. These names 
refer to the catalytic site of the enzyme. Cysteine endopeptidases or cysteine proteases (CPs) 
represent one of the major groups of proteolytic enzymes. These can be divided into about 30 
separate families based on their molecular structure. In mammals, three families of cysteine 
proteases were studied thoroughly (C1, C2, C14) before identification of legumain family 
(C13) as the fourth member of cysteine endopeptidases in mammals [9]. The majority of 
proteases are synthesized as inactive precursors being activated by proteolytic removal of the 
N-terminal propeptide. Removal of the propeptide can be facilitated either by the action of 
other proteases, or by autoactivation [10, 11].  
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The papain family (C1) is the most numerous in mammals and includes cathepsin B, H, L, S 
and others. The human genome is now known to contain 11 related cathepsins: B, F, H, K, L, 
O, S, V, X, dipeptidyl-peptidase I (cathepsin C) and cathepsin W [8, 12]. These lysosomal 
proteases are responsible for proteolysis intra-lysosomally/endosomally, but can also be 
secreted to act out side the cells [13]. The function of the cathepsins B, H, and L is 
degradation of intracellular proteins. Cathepsins K and S are implicated in the remodelling of 
bone and antigen presentation, respectively [14]. Despite their crucial functions in the body, 
the cathepsins have been found to be implicated in a number of diseases such as 
osteoporosis, rheumatoid arthritis, osteoarthritis and cancer, as well as in immune response 
and neurodegeneration [13].  
The calpain (C2) and the caspase (C14) families are located intracellularly in the cytosol [9]. 
Although functions of these two families of cysteine proteases have not been fully clarified, 
some of the caspases have been reported to play important roles in inflammation and 
apoptosis [8, 15]. The more recently discovered legumain family (C13) is the latest member 
of the family of cysteine proteases to date. The biological functions of this family of cysteine 
endopeptidases and its involvement in tumours, as well, will be discussed in detail later.  
1.1.2  Cysteine proteases and cancer 
A number of studies have been presented supporting that cysteine cathepsins contribute to 
tumour progression [2, 3]. In certain tumours, cysteine cathepsins are shown to become 
translocated from their intracellular compartments to the cell surface [1, 2]. Reports have 
revealed that several cathepsins were up-regulated during tumour progression, and they 
contributed to the capability for invasive tumour growth. In addition, cathepsins were shown 
to enhance angiogenic switching, tumour vascularity, invasion, proliferation of tumours, and 
to be involved in apoptosis [2-4, 16]. Calpains have also been described to be involved in 
cancer progression through a number of studies [7].  
The function of caspases as apoptotic initiators and executioners is a well known fact and has 
been demonstrated in a number of studies [17-21]. Caspase-1 has recently been shown to be 
down-regulated in the progression of ovarian and gastric cancers. On the other hand, intra-
prostatic administration of inducible caspase-1 and interleukin-12-containing adenoviruses 
caused local cell death and improvement of survival of adenocarcinoma-bearing mice [7]. 
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1.1.3  Cysteine protease inhibitors  
What have made protease inhibitors of considerable interest as drug candidates is 
observations that have connected tumour suppressing properties to cysteine protease 
inhibitors (CPIs) [5, 22-25]. Improper proteolytic activity has long been known to have 
prominent role in cancer as well as cardiovascular, inflammatory, neurodegenerative, 
bacterial, viral and parasitic diseases. Therefore, developing protease inhibitors is one of the 
most popular fields of drug discovery by pharmaceutical companies [26]. In normal tissues, 
the activity of proteases is tightly controlled in order to inhibit improper cleavage of 
signalling proteins [26]. 
During the last four decades, considerable amounts of effort have been made on developing 
inhibitors against cysteine proteases. In 1960, reports presented evidence for factors capable 
of inhibiting clotting activity of a thiol-dependent protease [27]. Furthermore, other groups 
described that cysteine (or thiol) protease inhibitors (CPIs or TPIs) were able to inhibit the 
plant cysteine proteases ficin and papain [27]. Further exploration of CPIs revealed that they 
belonged to a protein super-family, the cystatin super-family, which inhibited papain-type 
cysteine proteases [28].  
Interestingly, a recently published review listed more than ten cysteine protease inhibitors at 
different phases of clinical developments [15]. Among these novel inhibitors, the pan-
caspase inhibitor IDN-6556 has newly gained approval from the Food and Drug 
Administration (FDA) in USA to treat patients undergoing liver transplantation particularly, 
and other solid organ transplantations as well. Recently, several epoxysuccinyl-based 
inhibitors have been reported to have selective and potent inhibitory effects against papain-
like cysteine proteases, both in vivo and in vitro [29].  The epoxysuccinyl peptide derivatives, 
E64 and its synthetic analogues, have acquired most attention among the many natural 
cysteine protease inhibitors that have been isolated from dry-land microorganisms [15]. 
Besides, other natural inhibitors against cathepsin B, in addition to epoxysuccinyl peptides, 
have been identified; peptidyl aldehydes and aziridinyl peptides [30]. Newly, a number of 
cathepsin B inhibitors were disclosed, including bis-peptidyl inhibitors, cyclohexanon-based 
inhibitors, a series of azapeptides possessing an azaglycine residue and dipeptidyl nitrile [15 
62]. Dipeptidic nitriles are described as potent and selective cathepsin B inhibitors compared 
to the other inhibitors mentioned above [15, 31]. In addition, inhibitors of cathepsins K and S 
are, as well, in various phases of clinical development [15]. Similarly, a number of 
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compounds are being explored and developed as in-activators of calpain (C2) and caspases 
(C14) in connection with different types of diseases. Chagasin, the inhibitor family I42 
(MEROPS: the peptidase database) of cysteine proteases from protozoan parasites as well as 
prokaryotes and eukaryotes, was discovered. It was found to be tightly bound to the human 
cathepsins (B, H, K, and L). Although chagasin and the cystatins have different sequence 
homology, they were found to have remarkably similar binding interactions [32]. 
1.2  Legumain 
Legumain (asparaginyl endopeptidase, AEP) is a novel lysosomal protease belonging to clan 
CD. It is a member of the (C13) family of cysteine proteases, whereas all other known 
lysosomal cysteine proteases belong to C1 family (papains). Legumain has a highly restricted 
specificity, since it cleaves only substrates having an asparagine residue at P1 position [9]. 
Under acidic environments, however, legumain can also cleave bonds after aspartate [11]. It 
was first discovered by Csoma & Polgar in 1984 in germinating bean cotyledons, and was 
later found in several other plant seeds and tissues [33]. Moreover, the enzyme has also been 
described in the parasite blood fluke Schistosoma mansoni [34]. Cloning and sequencing of 
mammalian legumain cDNA, as well as isolation and characterization of the enzyme from 
pig kidney were done by Chen and co-workers in 1997 [9]. The cDNA of human legumain 
encodes a prepro-protein of 433 amino acid residues (49 kDa) [33]. 
By investigating the catalytic site of legumain (histidine and cysteine), it has been proposed 
that it has similar protein folds, and thus an evolutional relationship to the caspases, 
gingipains and clostripain [35]. Therefore, these enzymes are placed together in the clan CD. 
In recent years, many reports have associated legumain to a number of interesting and 
considerable functions. The enzyme has been described to play a prominent role in the 
processing of bacterial antigens by MHC II [36]. Legumain has also been reported to activate 
the zymogen progelatinase A (pro-MMP2) to gelatinase A (MMP2), which plays an 
important role in degradation of extracellular matrix [37]. Furthermore, data has been 
presented for a vital role of legumain in remodelling of extracellular matrix of renal proximal 
tubular cells via degradation of fibronectin, one of the main components of extracellular 
matrix, both in vivo and in vitro [38]. To support this result, it was shown that fibronectin 
processing could be inhibited by co-incubation of chloroquine, an inhibitor of lysosomal 
degradation. Moreover, legumain has been identified to inhibit formation of osteoclasts and 
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bone resorption by more than 60 % and it has, consequently, been termed osteoclast 
inhibitory peptide-2 (OIP-2) [39, 40].  It has also been described to be involved in the 
cornification of skin where CST6 deficient mice (not expressing cystatin M/E) showed 
abnormal skin cornification [41]. 
Legumain is not ubiquitously expressed in human tissues, but it has been shown to present in 
tissues from kidney, liver, spleen, placenta and heart [42]. In an attempt to localize legumain 
subcellularly in mouse tissues, it was visualized to be primarily located in lysosomes [43]. 
Very recently, legumain activity and expression were found to be dramatically increased 
when THP-1 cells (human monocytic cell line) were differentiated towards macrophages 
upon activation by PMA (phorbol 12 myristate 13-acetate) [44].  
1.2.1  Legumain processing and activation 
For optimal catalytic activity and stability, legumain requires an acidic environment [9, 45]. 
The acidic “window” for optimal legumain autoactivity has been described to be the pH 
range 3.5-4.5 [46] (figure 1). 
 
Figure 1: Autoactivation of legumain (AEP) (Li et al. 2003). Purified precursor (56 kDa) pig 
kidney legumain was incubated at the pH values indicated for 2 h at 37 oC.  Catalytic activity of 
legumain in each aliquot of the reactions (at different pHs) was measured using the substrate Z-Ala-
Ala-Asn-NHMec. 
In order to be activated, legumain has to go through two successive cleavages of C-and N-
terminal prepro-proteins, respectively, at different pH thresholds. Sequential cleavage after 
both asparagine and aspartic acid were found to be necessary for efficient enzyme activation 
resulting in the removal of a 110-residue C-terminal and 8-residue N-terminal propeptide, 
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respectively [46]. Like other lysosomal proteases, legumain is translated as preproform, 
transferred through the Golgi apparatus as the proform (56 kDa), and localized in late 
endocytotic compartments (lysosomes) as the mature enzyme (46 kDa) [47]. To support the 
fact that activation of prolegumain to active legumain is autocatalytic requiring acidic 
conditions [11, 46], one research group reported that legumain processing was inhibited 
when ovocystatin (egg-white cystatin), an inhibitor of legumain, was added to the cell lysates 
from stable transfectants of legumain cDNA [47]. To investigate processing of the proform 
of legumain in vivo, transfected HEK 293 cells with LGMN-cDNA were cultured in growth 
media containing different protease inhibitors. The processing protease for legumain was 
anticipated to be a papain-type cysteine protease, since only E64, not ovocystatin, inhibited 
legumain processing in vivo [47]. Later on, Li and co-workers [46] concluded that the final 
step in activating the mature legumain (46 kDa) is not autocatalytic, but occurs as a result of 
normal cellular processing involving other lysosomal proteases, since no processing beyond 
the 46 kDa product was obtained in vitro. Additionally, they documented that legumain 
found in living cells is a 36 kDa peptide, which is smaller than the autocatalytically activated 
46 kDa (figure 2). 
 
Figure 2: Cellular processing of legumain (AEP) adapted from Li et al. 2003  [46].  N323A mutant 
is a mutant form of AEP which is activated much more slowly than the wild type AEP at the same 
pH.  
1.2.2  Legumain in cancer 
As mentioned earlier, many proteases are up-regulated and involved in tumour progression, 
enhancing angiogenesis and invasion, and involved in degradation of extracellular matrix 
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proteins [2-4, 16]. Legumain has been documented to activate pro-MMP2, and hence 
increase degradation of extracellular matrix [37]. Evidence has been presented for 
overexpression of legumain in a number of solid tumours (i.e. breast carcinoma, colon 
carcinoma, lung carcinoma, prostate carcinoma, ovarian carcinoma, central nervous system 
tumours, lymphoma and melanoma) [42]. The expression has been demonstrated to be 
highest in prostate tumours. Notably, powerful correlation between its overexpression and 
enhancement of migratory and invasive properties in vitro and in vivo was documented. HEK 
293 cells overexpressing legumain were found to migrate and be more invasive than control 
HEK 293 cells. Moreover, similar findings were evident in vivo when mice were injected 
with control 293 cell tumour or legumain+293 cell tumour [42].  Interestingly, increased 
migration and invasion in vitro were partially inhibited by cystatin, a potent cysteine protease 
inhibitor. Although primarily in lysosomes, legumain has also been reported to appear 
extracellularly in the acidic tumour microenvironment, associated with matrix as well as cell 
surfaces [48]. In addition, legumain was found to be expressed by tumour angiogenic 
endothelial cells.  
Remarkably, legumain has been shown to activate the cell-impermeable prodrug legubicin 
which was synthesized by incorporating a peptide extension to the amino group of 
doxorubicin [42, 48]. Legubicin exhibited reduced toxicity relative to doxorubicin, and was 
found to be effectively tumoricidal in vivo without inducing any injury to other tissues 
normally expressing legumain (i.e. kidney). 
Recently, legumain was reported to be overexpressed in tumour associated macrophages 
(TAMs). TAMs contribute to promotion and proliferation of tumour cells by secreting 
growth factors and proangiogenic factors as well as metalloproteinases [49]. Notably, a full-
length murine legumain-based DNA vaccine showed increase in cytotoxic T-cell response 
against TAMs and hence reduction in TAM density. This in turn, led to suppression in 
tumour angiogenesis and marked improvement in survival of murine models of different 
tumour types [49]. Very recently, the same research group generated an oral legumain based 
minigene vaccine against TAMs which targeted tumour stroma [50]. This minigene vaccine 
induced immune responses directed against specific antigen epitopes while avoided 
responses against irrelevant antigen epitopes which may cause serious side effects. 
Administration of the legumain-based minigene vaccine to murine breast tumour models 
resulted in a marked suppression of tumour growth, metastasis, and angiogenesis. In support 
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to the above, in a study performed on colorectal cancer materials, it was concluded that 
legumain was overexpressed and had a prognostic value [51]. 
In a newly published study, legumain expression and its prognostic value were investigated 
in invasive breast cancer and non-cancerous breast tissues by immunohistochemistry [52]. It 
was observed that vesicular expression of legumain was dominant in 24 % of carcinomas and 
was associated with a more adverse outcome. These observations were in agreement with 
findings reported in previous work which suggested that overexpression of legumain was a 
prognostic factor and was correlated to more invasive and highly metastatic tumours [42, 
51].  
1.2.3  Inhibitors of legumain 
The clan CA enzymes (papain, calpains and cathepsins) are inhibited by the epoxide 
inhibitor E64 and use a catalytic triad in their active side. Clan CD cysteine proteases 
(legumains, caspases, gingipains, clostipains, and separase) are, on the contrary, resistant to 
inhibition by E64 and use a catalytic dyad in their active site [53]. In the literature, there has 
been described a handful of legumain inhibitors [53-57]. Cysteine protease inhibitors, the 
cystatins, are the most potent inhibitors of legumain described to date [23, 27, 43, 56, 57]. 
Cystatins M/E and C have been reported to be the most potent inhibitors of legumain among 
the members of the cystatin super family [56, 57]. In addition, other inhibitors of legumain 
have also been reported [9, 53-55]. When legumain was identified in mammals, Chen and 
co-workers tested a number of potential inhibitors of pig legumain [9]. Whereas general 
inhibitors of serine, aspartic and metalloproteases were not able to inhibit legumain, p-
chloromecuribenzoate, iodoacetate, iodoacetamide, and N-ethylmaleimide were reasonably 
effective inhibitors. Ovocystatin (from chicken egg-white) and recombinant human cystatin 
C, on the other hand, were slow, tight-binding inhibitors of legumain. A series of Michael 
acceptors (from the Michael reaction; α,β-unsaturated carbonyl compounds) based on the 
backbone Cbz-L-Ala-L-Ala-L-Asn (Cbz: benzyloxycarbonyl) have been demonstrated to be 
potent irreversible inhibitors of legumain. Among these; Cbz-L-Ala-L-Ala-L-Asn-CMK 
(CMK: Chloromethylketone) was shown to be the most potent inhibitor of pig legumain 
[54]. Subsequently, caspase specific inhibitors were shown to be capable of inhibiting 
legumain as well [55]. Further, new acylmethylketone inhibitors of legumain have been 
described, showing that 2, 6-dimethyl-benzoic acid 3-benzyloxycarbonylamino-4-carbomoyl-
2-oxo-butyl ester (MV026630) was the most potent [58]. Aza-peptide epoxides have also 
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been described as potent and selective inhibitors of legumain from Schistosoma manosi and 
pig kidney, and these showed little or no inhibition against other clan CA or CD proteases 
[53].  
1.3  Cystatins 
Cystatins are potent endogenous inhibitors of lysosomal cysteine proteases [28, 56]. The first 
member of this superfamily of enzyme inhibitors, ovocystatin, was described in the late 
1960s [14]. All functional cystatins are inhibitors of cysteine proteases of the papain (C1) 
family, and some also inhibit enzymes in the legumain (C13) family [14]. Cystatins regulate 
normal body processes through regulation of the activity of lysosomal cysteine proteases 
which can cause diseases when over-expressed, unless their activity is firmly controlled by 
inhibitors.  
There are three major families or types of cystatins; type 1 cystatins (A and B), type 2 
cystatins (C, D, M/E, F, G, S, SN, and SA), and type 3 cystatins (L- and H-kininogens). 
However, plant cystatins (phytocystatins) are also described as another type or family of 
cystatins. Type 1 cystatins (also called stefins) are mainly located intracellularly, whereas 
type 2 cystatins are secreted and located extracellularly, and type 3 cystatins intravascularly. 
Very recently, it was reported that carboxy terminal extended phytocystatins are bifunctional 
inhibitors of papain and legumain [59]. By investigating a panel of cystatin super family 
members, it was demonstrated that type 1 (stefins A and B) and (type 3) cystatins were not 
inhibitors of pig legumain. However, type 2 cystatins F and D were shown to be inhibitory 
and non-inhibitory of pig legumain, respectively [56].  On the other hand, type 2 cystatins C 
and M/E has outstandingly good inhibitory properties for all papain-like proteases 
investigated, as well as legumain [14]. 
The type 1 cystatins is a large group of small proteins, approximately 11 kDa in size, which 
lack disulfide bonds. Members of the type 2 cystatins are small proteins of approximately 
12–13 kDa containing two disulfide bonds towards their C-terminus. Type 3 cystatins (the 
kininogens) are large acidic proteins (45–65 kDa) containing one or several cystatin domains 
[14, 60].  
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1.3.1  Human cystatins and their roles in cancer 
It has been suggested that the change in the balance between cysteine proteases and their 
inhibitors (cystatins) could alter the susceptibility to cancer and tumourigenisity [8]. Many 
papers have reported that cystatins are strongly implicated in cancer [8, 22-25, 27, 42]. 
Below, some of the most important cystatins and their implication in cancer will be 
discussed: 
1.3.2  Stefin A  
A growing amount of evidence is suggesting that stefins A and B regulate initiation or 
propagation of the lysosomal cell death pathway [27].  The expression of stefin A has been 
found to be lost during progression of most prostate and breast cancers, as well as during 
tumourigenesis of skin, metastasis in oral carcinoma and lung cancer progression. 
Interestingly, exogenous stefin A was shown to inhibit motility of melanoma cells without 
affecting viability of the cells [27]. Recently, it was reported that levels of stefins A and B as 
well as the activity of cysteine proteases were significantly greater in small cell lung tumours 
when compared to normal lung tissues. Moreover, the survival probability of the patients was 
found to be better when levels of stefins A and B, and cysteine protease activity were 
elevated [24]. 
1.3.3  Stefin B 
Stefin B is a far more ubiquitous protein than stefin A, but its level of expression is varying 
between different tissues [27]. In tumour cells, it has been shown variation in stefin B levels 
when compared to normal non-tumour cells. Similar to exogenous stefin A, exogenous stefin 
B has been found to inhibit the motility of melanoma cells [27]. 
1.3.4  Cystatin C 
Cystatin C is a secreted protein found in all tissues and body fluids. Cystatin C is the most 
thoroughly studied cystatin in mammals. Mature human cystatin C is composed of 120 
amino acid residues and is synthesized as a preprotein [14]. The concentration of cystatin C 
in normal human serum is about 77 nM (1.16 µg/ml). Due to low molecular weight (15 kDa), 
cystatin C is efficiently eliminated via glomerular filtration. Consequently and due to other 
features, cystatin C is an excellent marker of the glomerular filtration rate. Expression of 
cystatin C in premalignant and malignant cells does not appear to alter much. On the 
contrary, some reports have shown elevated levels of cystatin C in sera, pleural effusions and 
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ascitic fluids gathered from cancer patients. The clinical value of these high levels of cystatin 
C in cancer patients, however, is yet to be clarified. In a study, it has been observed increased 
levels of cathepsin B and decreased level of cathepsin B/cystatin C complexes in lung cancer 
patients versus patients with non-cancerous lung disease or healthy individuals [27]. Cystatin 
C is assumed to be accumulated in pleural effusions rather than in the serum of cancer 
patients, it is therefore unable to inactivate serum cathepsin B. Cystatin C have been shown 
to inhibit in vitro tumour cell mediated degradation and invasion of extracellular matrix [27]. 
Cystatin C has been described as tumour growth factor-β (TGF-β) receptor antagonist and 
thus mediating effects on cellular signalling. Potent anti-cancer properties were obtained 
when cystatin C was studied in human SNB-19 glioblastoma cells and in a mouse model of 
glioblastoma. The tissue levels of cystatins C and M/E were obtained to be down-regulated 
in non small cell lung cancer (NSCLC) tumours when compared to healthy lung tissue [24]. 
These lower levels of type 2 cystatins, however, provided no prognostic information. In a 
current attempt to explore the underlying molecular mechanism in prostate cancer in vitro, 
cystatin C was reported to inhibit invasion of cancer cells in cooperation with TGF-β 
receptor II and androgen receptor (AR) pathways [61]. In a recent paper, photodynamic 
therapy (PDT) in combination with ovocystatin, have been documented to cause extensive 
tumour necrosis and significant decrease in serum vascular endothelial growth factor 
(VGEF) levels when compared to cystatin and PDT alone in a rat mammary tumour model 
[62]. 
1.3.5  Cystatin M/E 
Cystatin M/E is a low molecular mass protein that is secreted in both a glycosylated (17 kDa) 
and an unglycosylated (14 kDa) form. Cystatin M, and other cystatins, have been reported to 
be strongly involved in cancer [8, 22-25, 27, 42]. Ten of 12 established human breast cancer 
cell lines were shown to lack expression of cystatin M, while normal and premalignant cells 
expressed plentiful levels of the transcript. Additionally, scid (severe combined 
immunodeficient) mice orthotopically implanted with breast cancer cells expressing cystatin 
M, have been shown to considerably delay primary tumour growth and lower metastatic rate 
in lungs and liver when compared with mice implanted with mock controls (not expressing 
cystatin M) [25]. Based on these observations, it was suggested that the lack of cystatin M is 
contributed to the progression of human breast cancer.  
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Highly tumourigenic and metastatic breast cancer cell lines, MDA-MB-435S, were stably 
transfected with a cystatin M expression vector and studied for the outcomes of this 
expression on the malignant properties of the cells [22]. It was found that cystatin M 
expression reduced cell proliferation, migration, matrix invasion and tumour-endothelial cell 
adhesion. Notably, cell migration and matrix invasion appeared to be dependent on cysteine 
proteases, as both recombinant cystatin M and E64 blocked such processes. In support of 
these determinations, the activity of legumain and cathepsins (B and L) as well as cell 
proliferation and in vitro invasion were shown to be increased in metastatic oral cancer cell 
lines when cystatin M was silenced by siRNA [23]. As a consequence, it is assumed that 
cystatin M may have the ability to regulate the intracellular activities of their target cysteine 
proteases, beside their functions as secreted inhibitors of cysteine proteases. 
Very recently, the gene for cystatin M was reported to be frequently methylated, and hence 
inactivated in a number of breast cancer cell lines when compared to normal breast-tissue 
samples [63]. This hypermethylation of the cystatin M-promoter was shown to lead to 
inhibition of its transcription and silencing of cystatin M. Additionally, other reports have 
shown considerable reduction or loss of cystatin M expression in a number of skin cancer 
cell lines [27]. 
1.3.6  Cystatin F 
Cystatin F (also known as leukocystatin or CMAP) is also a secreted form of the type 2 
cystatins, composed of 126 amino acid residues [14] being predominantly expressed in 
hematopoietic cells [27]. The gene for cystatin F has been reported to be highly expressed in 
a number of metastatic human cancer cell lines, and has been contributed to a higher rate of 
liver metastasis [27]. Suppressing this gene has, interestingly, shown reduction in metastasis 
of the tumour cells to liver and spleen, and improved survival of tumour-bearing mice. 
Cystatin F acts in contrast to, and in a completely different manner from cystatins C and M 
by stimulating rather than suppressing metastasis to the liver. In addition, a 5-years survival 
study confirmed the correlation of higher levels of cystatin F to a significantly worse survival 
rate of the patients [27]. 
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2.  Aims  
Legumain has been shown to be a possible contributor to malignancy of cancer cells, and has 
been suggested as a marker for tumour invasion and metastasis. Contrary, cystatin M is the 
most potent endogenous inhibitor of legumain and has been suggested to be a tumour 
suppressor candidate. 
There might be a possible relationship between uncontrolled proteolysis by legumain and 
important regulatory and protective functions by cystatin M. 
This study wants to study the interplay between these proteins by: 
 Establishing methods in our laboratory for over-expressions of legumain and cystatin 
M. 
 Determining whether over-expression of cystatin M regulates the activity of legumain 
in the same cell. 
 Determining whether exogenously added cystatin M regulates intracellular legumain 
activity. 
 
Additionally, other objectives of this study are: 
 Characterization of molecular weight of active legumain in different cells and 
correlation with cathepsin B. 





3.1  Cell lines 
The following cell lines were used in this study: 
• A human embryonic kidney cell line (HEK 293 cells) (American Type Culture 
Collection, CRL-1573):  
HEK 293 cells are adherent cells at 37 oC, and loosen at room temperature. These 
cells grow well both in medium with or without serum [64].  
• A human acute monocytic leukaemia cell line (THP-1 cells) (American Type Culture 
Collection, TIB-202): 
THP-1 cells are a monocyte-like cell line isolated from a one year old boy with acute 
lymphatic leukemia. THP-1 cells are not attached to plastic under normal conditions. 
These cells become adherent upon stimulation with phorbol-12-myristate-13-acetate 
(PMA) (40 mg/ml) and they differentiate to macrophage-like cells [44].  
• A rat pheochromocytoma cell line (PC12 cells) (American Type Culture Collection, 
CRL-1721): 
PC12 cells are derived from a pheochromocytoma (tumour of adrenal gland 
producing catecholamines) of the rat adrenal medulla. These cells form loosely 
adherent, multicell aggregates which loosen by tapping the flask. 
• Various human melanoma cell lines (Rikshospitalet University Hospital HF; RUH-
HF, table 1). 













3.2 Chemicals and reagents 
2-mercapto ethanol     Sigma-Aldrich, St. Louis, USA 
Acetic acid (100 %)     Gibco, Life tech., Invitrogen AS, Norway 
Acrylamide/Bis solution (37.5:1)    
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(Monomer solution)      BioRad, Hercules, USA 
Agarose      MedProbe, Oslo, Norway 
Albumin      Pierce, Boule Nordic AS 
Ammonium persulphate    BioRad, Richmond, CA, USA 
Brij 35       Sigma-Aldrich 
Bromophenol blue     Sigma-Aldrich 
CA074  Calbiochem (Merck, Darmstadt, 
Germany) 
C6H5Na3O7.2H2O     Merck  
CaCl2.2H2O      Merck 
CHAPS      Sigma-Aldrich 
Dye reagent concentrate (protein assay)  Bio-Rad 
DL-Dithiotreitol (DTT)    Sigma-Aldrich 
DMEM (HEK 293)     Invitrogen, art. No. 41966-052 
DMEM (PC12)     Gibco, art. No.42430-025 
ECL       GE Healthcare/ Amersham, England 
E64       Sigma-Aldrich 
Ethanol      Arcus, Oslo, Norway 
Ethidium bromide (1 %)    Sigma-Aldrich 
Non-fat dry milk     Normilk, Stavanger, Norway 
Fungizone       Bristol-Meyers Squibb, NY, USA 
FBS       Gibco  
Glucose      Sigma-Aldrich 
Glycine      VWR international, England 
HBr       Sigma-Aldrich 
HEPES      Sigma-Aldrich 
HS       Invitrogen 
Isobutanol      Merck 
KCl       Prolabo, Paris, France 
KHP2PO4      Prolabo 
Lipofectamine 2000     Invitrogen 
Methanol      Merck 
MgSO4.7H2O      Prolabo 
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Na3C6H5O7.2H2O (sodium citrate)   Merck 
NaCl       Prolabo 
Na2EDTA      Chemi-Technique, Berlin, Germany 
Na2HPO4      Merck 
Na2HPO4.H2O      Merck 
n-octyl-β-D-glucopyranoside    Sigma-Aldrich 
Papain       Sigma-Aldrich 
Penicillin-Streptomycin    Sigma-Aldrich 
PMA       Sigma-Aldrich 
Ponceau S solution     Sigma-Aldrich 
Precision Plus Protein Standard   BioRad 
RPMI 1640 with L-Glutamin    PAA Laboratories GmbH, Austria 
SDS       BioRad 
Sodium pyrovate     Gibco  
TCA       Merck 
TEMED      BioRad 
Tris (base)      Sigma-Aldrich 
Tryptan blue      Sigma-Aldrich 
Tween 20      BioRad 
X-ray developer LX24    Kodak, Oslo, Norway 
X-ray fixer AL 4     Kodak 
Z-Ala-Ala-Asn-NHMec  Department of Biochemistry, University 
of Cambridge, UK 
Z-Arg-Arg-NHMec     BACHEM, Bubendorf, Switzerland 




4.1  Cell culturing and harvesting 
Three different cell lines were cultured and used in the experiments: HEK 293, THP-1 and 
PC12 cells. All work with cells was carried out in a LAF bench using aseptic techniques. For 
cell culturing, a 75 cm2 Corning cell culturing flask was used, while for experiments, six-
well plates (Corning) were used. The cells were incubated at 37 oC in a humidified 5 % CO2 
atmosphere. 
4.1.1   HEK 293 cells 
HEK 293 cell culturing was performed in a Dulbecco’s Modified Eagles Medium (DMEM) 
with high glucose content (appendix). The growth medium was changed every third/fourth 
day. Frozen cells (in liquid nitrogen tank) were thawed at 37 oC and cultured in 10-12 ml 
growth medium in a cell culturing flask. The cells were split whenever 80-90 % confluent, 
usually every fourth day. Trypsin-EDTA (0.5 % in serum-free DMEM) was added to detach 
the cells, and subsequently deactivated by adding growth medium containing 10 % serum. 
The cells were centrifuged (800 rpm, 5 minutes) and the pellet was resuspended in the 
growth medium.  Finally, 1x106 cells were transferred to a flask containing 10-12 ml growth 
medium (appendix). For experiments, cells were counted as described in 4.1.4. 
4.1.2 THP-1 cells 
Frozen THP-1 cells were thawed at 37 oC and cultured in 10 ml growth medium (appendix). 
The cells were split whenever the concentration of the cells was 1x106  cells/ml, usually once 
weekly. The cells were centrifuged (800 rpm, 5 minutes), and the pellet was resuspended in 
growth medium followed by transferring 1x106 cells to a cell culturing flask containing up to 
10 ml growth medium. The growth medium was refreshed every third day by adding 10 ml 
fresh medium. Cell counting was performed as described in 4.1.4. For experiments, THP-1 
cells were PMA stimulated (40 ng/ml) for 24 hours and washed with RPMI without additives 
(appendix). 
4.1.3 PC12 cells 
Frozen PC12 cells were thawed at 37 oC and cultured in 11 ml DMEM with high glucose 
content (appendix). Cells were split whenever 80-90 % confluent (approximately every 
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third/fourth day). Old medium was aspirated and the flask was hit to dislodge the cells. Fresh 
medium was added to break clusters by pipetting. One ml of this suspension was added to a 
culturing flask containing 11 ml fresh medium and the cells were incubated at 37 oC and 5 % 
CO2. The medium was renewed every 2-3 days. For experiments, the cells were counted as 
described in 4.1.4. 
4.1.4 Cell counting 
In order to seed the cells (HEK 293, THP-1 and PC12) for experiments, the cells were 
counted by using a Bürker counting chamber. The cell suspension (100 µl) was added to 100 
µl 0.4 % sterile filtered tryptan blue (appendix) in an eppendorf tube, and applied to the 
chamber. The cells in the diagonals were counted under microscopy and quantified using the 
following equation: 
n (average of number of the cells in diagonals) x 4.2/100 = Cells x 106 per ml. 
4.1.5 Cell harvesting 
To harvest the cells (HEK 293, THP-1 and PC12), medium was aspirated and the cells were 
washed 1-3 times with 0.5-1 ml of PBS (for HEK 293 cells, 0.5 ml pre-warmed PBS was 
used because cells could detach) before adding 0.5 ml lysis buffer (appendix) to each well of 
six-well plates. In experiments for total inhibitory analysis, the media were collected as well. 
The cell lysates were transferred to eppendorf tubes and exposed to three cycles of freezing 
and thawing (-70 and +30 oC, respectively). Afterwards, the samples were centrifuged at 
10000 g, and 4 oC for 5 minutes. The media samples were centrifuged as well and the 
supernatants were transferred to new eppendorf tubes. When un-stimulated THP-1 cells were 
harvested, the cells were first centrifuged (800 rpm for 5 minutes) and subsequently the 
media were aspirated before the cells were washed in PBS and lysed in lysis buffer as 
described above. 
 
4.2  Amplification,  purification and verification of  plasmids 
The LGMN-plasmid coding for rat legumain (rLGMN) was kindly provided by Professor 
Kazumi Ishidoh, Division of Molecular Biology, Institute for Health Sciences, Tokushima 
Bunri University, Japan. This was prepared by inserting the full length rLGMN-cDNA (1357 
bp) into the polylinker (EcoRI-site) of the pTarget vector (5.67 kb) (Promega) [65] (figure 
3A). 
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The human CST6-plasmid (hCST6) coding for cystatin M and the empty pTracer-CMV2 
vector (6.2 kb; Invitrogen, Carlsbad, CA, USA) [66] were gifts from postdoc. Jon Briggs, 
Department of Tumour Biology, Rikshospitalet University Hospital HF (RUH-HF), Oslo, 
Norway. The plasmids were originally provided by Professor Daniel Keppler, Department of 
Cellular Biology & Anatomy, Louisiana State University Health Science (LSUHSC), USA. 
The CST6-plasmid contained the full length hCST6-cDNA (475 bp) subcloned into the 
KpnI/EcoRI sites in the polylinker of the mammalian expression vector pTracer-CMV2 
(figure 3B).  
        
Figure 3: Cycle maps of pTarget (A) and pTracer-CMV2 (B) vectors. The vector expressions of 
inserted genes is regulated by the human cytomegalovirus (CMV) promoter and terminated by 
simian virus (SV40) late poly adenylation signal (PA) and bovine growth hormone (BGH) PA, 
respectively. Both plasmids contain an ampicillin resistance gene. A) The pTarget vector has two 
plasmid subcloning sites: a T-vector (a linearized vector containing a thymidine at the 3`-ends) and 
a multiple cloning site (MCS). For generation of stable transfectants, the vector contains the 
neomycin phosphotransferase gene, expressed by SV40 enhancer promoter and terminated by a 
synthetic PA. B) The pTracer vector with cycle 3-GFP (green fluorescent protein) gene. For stable 
transfection, the vector contains a zeocin resistance gene, expressed by PEF1 and PEM-7 promoters 
and terminated by SV40 PA. 
In order to produce plasmids in high quantities, chemically competent E. coli were 
transformed (a 50 µl vial of One Shot® cells and 1-2 µg plasmid). For each plasmids, 
plasmid-transformed E. coli stocks in glycerol were frozen at -70 oC. In short, either directly 
after transformation or from glycerol stocks of E. coli, plasmids were isolated and purified 
(mini- and maxi-preps) in order to yield pure plasmids. The plasmids (2 µg) were digested 
(37 oC overnight) by suitable restriction endonucleases (EcoRI for LGMN and KpnI/EcoRI 
A) B) 
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for pTracer and CST6, respectively) and loaded on a 1 % agarose gel (at 100 V for 1-2 hours) 
parallel to a DNA-standard to verify the size of the inserted cDNAs and vectors (appendix). 
4.2.1 Determination of plasmid concentration  
The concentrations of the isolated plasmids were estimated by measuring optical density 
(OD). The absorbance was measured in a Gene Quant instrument. The samples were 
prepared by adding 180 µl distillated water to 2 µl of plasmid solution in a cuvette.  The 
absorbance was measured at two wave lengths (260 and 280 nm) and the concentrations of 
DNA solutions were calculated using the following equation: 
 
OD (at 260 nm) x 50 (DNA factor) x 90 (sample dilution factor) x 1000 = 
      Plasmid concentration µg/µl 
 
4.3  Transient transfection of HEK 293 cells 
HEK 293 cells were used for transient transfection with LGMN- and CST6-plasmids. The 
transfection method used was based on liposome-mediated transfection by using 
lipofectamine 2000 (Invitrogen) as the lipid reagent. Liposomes are synthetic analogues of 
natural cellular membranes made of phospholipid layers. Phospholipids contain one water 
soluble end, and opposite water insoluble end, which allows complex formation with DNA 
and form spherical liposomes under aqueous conditions. 
4.3.1 Transient transfection with LGMN-plasmid 
Prior to transfection, HEK 293 cells were split, counted and seeded (0.3-0.5 x105 cells/well) 
onto six-well plates and incubated for 24-72 hours at 37 o C. A number of experimental 
adjustments were carried out to increase the efficacy of the transfection process (table 2). The 
main adjustments were titration of cell density, culturing in DMEM with or without serum 
and determining the proper amount of plasmid-DNA, as well as plasmid to liposome ratio. 
At the day of transfection, both plasmid and lipofectamine 2000 were diluted with DMEM, 
mixed gently and incubated at room temperature for 30 minutes. One ml of the lipid-plasmid 
complex was added to each well. The growth media was removed from the cells immediately 
before overlaying the lipid-plasmid complex (appendix). 
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(TF)  time (h) 
Harvesting time 




1 5  20  1:4 Yes/No Yes 48  48  
0.5 1 1, 2.5, 5  20  1:20, 1:8, 1:4 Yes Yes 48  48  
0.5 1 1, 2.5, 5  10  1:10, 1:4, 1:2 Yes No 24  48  
0.3 3 2, 5  5  1:2 Yes No 24  48, 72, 144  
 
0.3 3 2.5, 5, 10, 20  5 1:2, 1:1, 2:1, 
4:1 
Yes/No No 3, 6, 9,  24  48  
 
4.3.2 Determination of transfection efficacy using maxFP-Green plasmid 
In order to evaluate the efficacy of the transfection method (liposome-principle), the cells 
were transfected by maxFP-Green plasmid (figure 4), cloned from the copepod Pontellina 
plumata (a tiny crustacean that lives among plankton and is an important food source for 
many fish) [67]. Cells (5 x105 cells/well) were seeded onto six-well plates two days prior to 
transfection. Ten µl lipofectamine 2000 and 2.5 µg plasmid were diluted in DMEM without 
serum and antibiotics separately, mixed and incubated at room temperature for 30 minutes, 
before overlaying the cells. In the case of a successful transfection, the expressed fluorescent 
maxFP-Green will be visualized under fluorescence microscopy as dark green spots. 
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Figure 4: Cyclic map of maxFP-Green-C vector. The vector uses the immediate early promoter of 
cytomegalovirus (CMV) to express the maxFP-Green plasmid (encoding the green fluorescent 
protein maxFP-Green). Plasmid expression is terminated by simian virus (SV40) (PA). The plasmid 
also contains kanamycin- and neomycin-resistance genes, expressed by bacterial promoter P (in 
bacteria) and SV40 early promoter in mammalian cells (for stable transfectants), respectively. The 
expression of antibiotic genes is terminated by Herpes simplex virus (HSV) thymidine kinase (TK) 
PA. 
4.3.3 Transient transfection with  CST6-plasmid 
HEK 293 cells (2.5-3 x105) were seeded onto six-well plates three days prior to transfection. 
The plasmids CST6 and pTracer (empty vector) (4 µg/well) as well as lipofectamine 2000 
(10 µl/well) were diluted in DMEM without antibiotics and serum. The solutions were 
mixed gently and incubated at room temperature for 30 minutes before adding to the cells. 
The transfection solution was aspirated after 24 hours and HEK 293 medium was added. 
After 24 hours (48 hours after start of transfection), the media from the cells were collected 
and the cells were harvested and lysed in lysis buffer (appendix). 
4.4 Protease activity measurements 
The microplate reader Wallac Victor 3, 1420 Multilabel Counter (PerkinElmer), supplied 
with the Workout software was used under measurements of protease activity, total 
inhibitory activity against cysteine proteases and total protein concentration. 
4.4.1 Proteolytic activity of legumain 
The activity of legumain in whole cell lysates and elution fractions after size exclusion 
chromatography (4.8) was measured fluorimetrically using Z-Ala-Ala-Asn-NHMec as the 
specific substrate [9, 68]. Upon cleavage by legumain, the fluorescent leaving group –
NH2Mec caused increase in fluorescence.  
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Twenty µl of cell lysates or blank were added to a black 96-well microplate (Costar). After 
addition of 100 µl assay buffer with DTT (pH 5.8) (appendix) and 50 µl substrate (final 
concentration of substrate in the wells were 10 µM) by auto-injectors, a kinetic measurement 
based on increase in fluorescence (∆F/s) over 120 minutes (some times 10 or 30 minutes) 
was carried out. The temperature was kept at 30 oC and all measurements were performed in 
triplicate. The excitation and emission wavelength were 360 and 460 nm, respectively 
(appendix). 
4.4.2 Proteolytic activity of cathepsin B 
The activity of cathepsin B was measured in the elution fractions from size exclusion 
chromatography (4.8).  The activity was measured in the same way as legumain, but using 
the substrate Z-Arg-Arg-NHMec [44]. Twenty µl of the fractions were added to black 96-
well plates and the temperature was kept at 30 oC in the Wallac Victor. After addition of 100 
µl buffer (pH 5.5; appendix) and 50 µl substrate solution (final concentration of substrate in 
the wells were 20 µM) by auto-injectors, a kinetic measurement was performed and the 
increase in fluorescence per second (∆F/s) was calculated over 10 minutes (appendix). 
4.5 Measuring total inhibitory activity against cysteine proteases 
To measure inhibitory activity against cysteine proteases, an indirect method was used which 
was established in an earlier work in our research group [69]. Inhibitory activity against 
cysteine proteases was measured by comparing the samples at the same degree of inhibition 
(50 %). A range of dilutions of media and a standard curve were used in order to estimate 
which dilution corresponded to a 50 % inhibition of papain (in media) and legumain (in 
fractions from 4.8). In this study, an inhibitory unit (IU) was defined as the concentration of 
inhibitory activity needed to inhibit 50 % of enzyme activity. Total inhibitory activity was 
calculated as IU/mg total protein for fractions, and IU/ml for media samples. 
4.5.1 Total inhibitory activity against papain 
The total inhibitory activity in media from CST6-transfected cells were determined by using 
papain as a target enzyme and measuring papain activity with the fluorescent synthetic 
peptide substrate Z-phenyl-arginin-NHMec. Before starting the assay, media samples were 
boiled (100 oC, 5 minutes) to inactivate any proteolytic enzymes present capable of cleaving 
the papain substrate (cystatins are resistant to high temperatures). Papain was diluted in 50 
mM sodium acetate buffer (pH 4.5) and a 100 000 X dilution (appendix) was used in the 
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measurements, based on the previous work [69]. The measurements were performed using a 
weakly acidic phosphate buffer (papain assay buffer, pH 6.5) containing DTT. Black 96-well 
micro plate was used in this purpose, and the temperature was kept at 37 oC. Twenty µl of 
papain solution (100 000X) and 17 µl samples were added to the wells, except blank (20 µl 
sodium acetate + 17 µl papain assay buffer without DTT). Using auto-injectors, the wells 
were added 83 µl assay buffer and subsequently 50 µl substrate (final concentration 10 
µM/well). Fluorescence (∆F/s over 10 minutes) was measured at excitation and emission 
wavelength 355 and 460 nm, respectively (appendix). 
4.5.2 Inhibitory activity against legumain 
Using the same method as described for papain, inhibitory activity against legumain in media 
from CST6-transfected cells was measured. The fractions with highest legumain activity 
from analytical size exclusion chromatography (4.8) were used for this purpose. The 
fractions (20 µl) were added to black 96-well plates and 17 µl of medium from pTracer or 
CST6-transfected HEK 293 cells were added to the wells. Using auto-injectors, legumain 
assay buffer (appendix) was added (83 µl) to the wells followed by 10 minutes incubation 
time, before addition of 50 µl legumain substrate solution. The same protocol as for papain 
was used to perform a kinetic measurement based on ∆F/s over 10 or 120 minutes, when the 
temperature was kept at 30 oC. 
4.6 Total protein determination 
To measure total protein concentration in cell lysates, the Coomassie based procedure as 
described by Bradford was used [70]. The colour reagent (protein assay dye reagent 
concentrate) was diluted 1:5 in dH2O and sterile filtered (appendix). The measurements were 
performed according to the manufacturer (Bio-Rad Laboratories, Hercules, CA, USA) in the 
Wallac Victor, measuring absorbance at 595 nm. A standard curve was established by using 
bovine serum albumin (BSA, 50-300 µg/ml) for the calculation of concentration of proteins 
in cell lysates (appendix).  
4.7 Immunoblotting 
In order to prepare samples for electrophoresis analysis on SDS-polyacrylamide gels, 
proteins in cell lysates were concentrated by TCA precipitation (appendix). The total protein 
concentration was adjusted depending on results from the total protein measurements (4.6). 
Eventually, samples containing 10-20 µg total protein were run parallel to 2.5 µl of the 
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standard precision plus (Bio-Rad) on a 12 % SDS-polyacrylamide gel prior to blotting to a 
nitrocellulose membrane. After blotting for 45-60 minutes, the membrane was coloured by 
Ponceau S-solution, in order to confirm a successful blotting process. After washing by 
distillated water, the membrane was placed in T-TBS for 10 minutes. The membrane was 
blocked with 5 % non-fat dried milk in T-TBS prior to incubating with the primary antibody 
polyclonal rabbit anti human legumain (Abcam). The primary antibody was diluted in 
blocking solution (1:5000) as recommended by the manufacturer and incubated with the 
membrane overnight at 4 oC under gentle agitation.  After washing in blocking solution, the 
membrane was incubated with the secondary antibody goat anti rabbit IgG HRP-conjugate 
(Bio-Rad) diluted in blocking solution (1:3000) for 1 hour. Then, the membrane was washed 
once by blocking solution and several times by T-TBS, before detection of immunoreactive 
bands by enhanced chemiluminescence ECL Western Blotting Detection System (Amersham 
Biosciences; appendix). 
4.7.1  Quantification of Western bands 
In order to quantify the bands obtained after the Western blotting analysis, images of the 
bands on a film was captured by GeneSnap scanner, version 6.05.01 (SynGene). The images 
were then densitometrically analyzed by using the automatic image analysis software 
GeneTools (SynGene). The software makes it possible to compare the graphical 
presentations of the different bands on the film by plotting the graphs in the same page. The 
relative differences in intensity of the bands are then calculated by determining the ratio of 
area between the bands of interest. 
4.8 Analytical size exclusion chromatography 
To investigate the molecular weight of proteins giving rise to the legumain (and cathepsin B) 
activity that appears in HEK 293, THP-1 and PC12 cells, the cell lysates were subjected to 
size exclusion chromatography. Samples (200 µl) were applied to a Superdex 75 10/30 
column (Amersham Biosciences, Buckinghamshire, UK) equilibrated with buffer (appendix). 
Elution of the column was controlled by a FPLC-system, keeping flow to 0.5 ml/min and 
collecting fractions of 300 µl. Estimation of the molecular weight of proteins/activity eluting 
from the column was done by comparing with the following gel filtration standards (all from 
Amersham Biosciences): ribonuceases A (13.5 kDa), chymotrypsinogen A (25 kDa), 
ovalbumin (43 kDa) and bovine serum albumin (67 kDa). 
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5. Results 
5.1 Amplification, purification and verification of LGMN and CST6 
In order to have enough plasmids to perform transfection experiments, the plasmids for 
LGMN, CST6 and the empty vector (pTracer-CMV2) were amplified and purified by using a 
JETSTAR plasmid purification kit (Genomed, appendix). To verify that the plasmids were 
intact, they were digested by restriction endonucleases (EcoRI for LGMN and KpnI/EcoRI 
for pTracer and CST6, respectively) overnight, before running on agarose gels (figure 5).  
In the case of the LGMN-plasmid, gel electrophoresis revealed two distinct bands in the lane 
with the digested plasmid (figure 5A, lane 3), whereas only one band could be observed in 
the lane with undigested plasmid (lane 2). Empty pTarget vector was not available as control. 
By comparing the obtained bands from the digested plasmid (lane 3) with a DNA standard 
(lane 1), it was concluded that the lower band corresponded to a size of about 1300 bp and 
the upper band of approximately 5700 bp. The inserted LGMN-cDNA sequence consists of 
1357 bp, and the pTarget vector of 5657 bp which is in agreement with the observed 
restriction bands. 
For the CST6-plasmid, it was observed two bands in the lane with digested CST6 (figure 5B, 
lane 5) and only one band in the lanes with undigested pTracer vector, digested pTracer and 
un-digested CST6 (lanes 2, 3 and 4, respectively). By comparing the bands from the digested 
CST6-plasmid with the DNA-standard (lane 1), it was concluded that the lower band 
corresponded to the CST6-cDNA with a molecular size of 475 bp and the upper band to the 









                  
Figure 5: Agarose gel electrophoresis of purified LGMN (A) and CST6 (B) plasmids. E. coli were 
transformed with plasmids, and the plasmids were isolated and purified using a JETSTAR plasmid 
purification system. The DNA (2 µg) were digested with restriction nucleases and run on 1 % 
agarose gel for 2 hours at 100 V. A) LGMN-plasmid. 1) DNA standard (100 bp DNA ladder); 2) Un-
digested plasmid; 3) EcoRI-digested plasmid. B) CST6-plasmid. 1) DNA standard (100 bp DNA 
ladder); 2) Un-digested empty pTracer vector; 3) EcoRI/KpnI-digested pTracer; 4) Un-digested 
CST6-plasmid; 5) EcoRI/KpnI-digested-CST6. Arrows indicate sizes of bands in the DNA ladder.  
5.2 Transfection of HEK 293 cells with LGMN-plasmid 
HEK 293 cells were transfected with the LGMN-plasmid to establish a transient and/or 
stable cell line which expresses high levels of legumain. As table 2 indicates, a number of 
experimental adjustments were performed in order to optimize the transfection conditions of 
HEK 293 cells with the LGMN-plasmid. The use of 20 µl liposomes was found to be toxic to 
the cells, especially when the liposome-plasmid complex was allowed to be in contact with 
the cells for 48 hours. The cells detached easily and formed loosely floating cell aggregates. 
The toxicity of liposomes was reduced when the transfection complex was not allowed to be 
in contact with the cells for more than 24 hours. However, the use of 5 µl liposomes, and in 
most cases 10 µl, tended to be preferred by the cells, despite long stimulating time (48 hours) 
with the transfection complex (not shown). The absence of serum from the growth media 
during culturing was also observed not to be preferred by the cells, as they detached easily 




  600 bp 
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To evaluate transfection efficiency, legumain activity was measured in cell lysates. No 
increase in legumain proteolytic activity was observed in LGMN-transfected cells compared 
to controls (figure 6). Different amounts of LGMN-plasmid and liposomes did not cause any 
increase in legumain activity (figure 6A and B, respectively). Corresponding immunoblots of 
legumain verifying unsuccessful transfection are shown in figure 7, lanes 3 and 4. Only in 
one of many experiments using serum free media, a slight increase in legumain activity could 
be observed (figure 6C).  
 
Figure 6: Proteolytic activity of legumain in HEK 293 cells transfected with LGMN-cDNA. A) 
Cells (5 x 105) were seeded onto 6-well plates the day prior to transfection using 5 µl lipofectamine 
2000 for 24 hours. The transfection medium (+FBS) was free from antibiotics. One representative 
experiment is shown (n=3). B) Cells (3 x 105) were seeded onto 6-well plates 3 days prior to 
transfection with 5 µg LGMN-plasmid. Transfection was performed using 5 or 10 µl lipofectamin 
2000 (for 24 hours) and free from serum and antibiotics (n=2). C) Cells (5 x 105) were seeded onto 
6-well plates the day prior to transfection. Transfection was aided by 5 µl lipofectamine 2000 
(including liposome controls). The transfection media was either free from antibiotics (+FBS÷P/S), 
or from both serum and antibiotics (÷FBS÷P/S) (n=1). All cells were harvested and lysed 48 hours 
after start of transfection. The fluorogenic peptide Z-Ala-Ala-Asn-NHMec was used as the substrate 
for legumain and activity data were adjusted to µg total protein (see methods).  
5.2.1 Immunoblotting of legumain 
To investigate whether transfection of HEK 293 cells with the LGMN-plasmid had resulted 
in a regulation of legumain protein expression, immunodetection of legumain in the cell 
lysates using an anti-legumain antibody (1:5000) was performed. The antibody gave three 
strong bands of approximately 57, 45 and 29 kDa, respectively (figure 7A). Molecular 
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weight of these bands was calculated using a protein standard (the standard precision plus, 
Bio-Rad). The 45 kDa band was composed of a double band. Untreated HEK 293 cells 
(control) showed high expression of all three legumain bands (lane 1). Consistent with the 
results from legumain activity measurements, it was no increase in intensity of the bands in 
the cell lysates from LGMN-transfected cells compared to controls. In one experiment, 
however, slight increase in band intensities could be seen in cell lysates of transfected cells 
with 5 or 10 µg LGMN-plasmid, respectively (figure 7A, lower bands in lanes 7 and 8). 
These bands (figure 7A, lower bands in lanes 5-8) were scanned and their intensities were 
determined by the automatic image analysis software GeneTools (SynGene; figure 3B). 
Increase in band intensities were 31, 80 and 131 % in cell lysates from HEK 293 cells 
transfected with 2.5, 5 and 10 µg LGMN-cDNA, respectively, compared to control.  
 
Figure 7: Representative immunoblots of legumain (A) and corresponding band intensity (B) in 
HEK 293 cell lysates transiently transfected with LGMN-cDNA. A) Transfection was aided by 
lipofectamin 2000. The cell lysates were TCA precipitated and 12.5 µg total protein were loaded in 
each well. (1) Control (untreated). (2) Cells transfected with 1 µg plasmid. (3) Cells transfected with 
2.5 µg plasmid. (4)  Cells transfected with 5 µg plasmid. Lanes 2-4; 10 µl liposome.  (5) Liposome 
control. (6) Cells transfected with 2.5 µg plasmid. (7) Cells transfected with 5 µg plasmid. (8) Cells 
transfected with 10 µg plasmid. Lanes 5-8; 5 µl liposome.  B) Intensities of the lower bands (29 
kDa) in A (lanes 5-8), determined by automatic image analysis software; GeneTools (SynGene). The 
intensities are given as percent of control (liposome treated). 
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5.3 HEK 293 cells were efficiently transfected by liposomes  
Since the method was not previously established in the laboratory and the legumain activity 
data and Western blots in HEK 293 cells transfected with the LGMN-plasmid showed no 
regulation of legumain, it was desirable to check the transfection efficacy by using maxFP-
Green-plasmid (Amaxa) and lipofectamin 2000. Importantly, it was necessary to test the 
technical aspects under performance of transfections.  
HEK 293 cells were transfected by 2.5 µg maxFP-Green and 10 µl liposomes without serum 
and antibiotics, and the transfection complex was changed with fresh medium 24 hours after 
start of transfection. Upon expression of the fluorescent maxFP-Green protein, the cells can 
be visualized as green cells under fluorescence microscopy. The transfection efficacy of 
HEK 293 cells with maxFP-Green plasmid appeared to be 70-80 % (figure 8) determined by 
green versus colourless cells. That indicated that the transfection method and optimized 
conditions used during the experiments were sufficient for successful transfection. 
     A)            B) 
 
Figure 8: Evaluation of the transfection efficacy of HEK 293 cells by using maxFP-Green 
plasmid.  Cells (5 x105) were seeded onto 6-well plates 2 days prior to transfection with 2.5 µg 
maxFP-Green plasmid using 10 µl lipofectamine 2000 and medium without serum and antibiotics. 
The transfection complex was changed with fresh medium 24 hours after start of transfection and 
the cells were visualized 48 h after start of transfection. A) A section of cells visualized by light 
microscopy (enlarged 10 x). B) The same section of the cells visualized by fluorescence microscopy 
(10 x). The green spots seen in (B) are the expressed maxFP-Green protein (cloned from Pontellina 
plumata). 
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5.4 Over-expression of cystatin M  
5.4.1 Over-expression of cystatin M in CST6-transfected HEK 293  
In spite of negative results from the transfection experiments of LGMN-plasmid in HEK 293 
cells, the cells were transfected with CST6-plasmid. The purpose of this opposed strategy 
was to generate a cystatin M over-expressing cell line, and to characterize the influence of 
cystatin M on legumain activity. 
Total inhibitory activity against papain in the conditioned media from CST6- and pTracer-
transfected HEK 293 cells was measured in order to investigate if the transfected cells had 
expressed and secreted functional cystatin M. In all experiments performed (n=3), the total 
inhibitory activity (IU/ml) against papain in media from CST6-transfected cells was higher 
than in media from pTracer-transfected cells (figure 9). The increase in total inhibitory 
activities varied and was 36, 75 and 104 %, respectively.  
 
Figure 9: Total inhibitory activity against papain in media from CST6- and pTracer-transfected 
HEK 293 cells. Cells (2.5-3 x105) were seeded 3 days prior to transfection with 4 µg pTracer 
(control; open bars) or 4 µg CST6 (closed bars) plasmids using 10 µl lipofectamine 2000 for 24 
hours. The transfection media was free from both FBS and P/S. Media and cells were harvested 48 h 
after start of transfection. Total inhibitory activity (IU/ml) was measured fluorimetrically using 
papain as the target enzyme and is given as percent of control (empty vector; pTracer) (n=3). 
5.4.2 Over-expression of  cystatin M in CST6-transfected melanoma cells  
A panel of melanoma cell lines (table 1) were transfected with CST6 or pTracer by postdoc. 
Jon Briggs at RUH-HF. The aim was to study over-expression of cystatin M in these cells, 
and its correlation with legumain activity. Media from the established melanoma cell lines 
A-375, FEMX-I, HHMS and SKMEL-28, and the malignant melanoma cell lines isolated 
from patients MM 11, MM 35 and MM 69b, all transfected with CST6 or empty vector 
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(pTracer), were received for measurement of total inhibitory activity against cysteine 
proteases. Over-expression of cystatin M was observed in media from all melanoma cell 
lines transfected with CST6-plasmid when compared to pTracer-transfected cells (figure 10). 
Among these cell lines, CST6-transfected SKMEL-28 showed highest increase in total 
inhibitory activity (IU/ml) of 41 % followed by MM 11 with 39 % compared to control. In 
MM 69b cells, however, over-expression of cystatin M was minimal (figure 10).  
 
Figure 10: Total inhibitory activity against papain in media from established melanoma and 
malignant melanoma cell lines transfected with CST6 or pTracer-plasmid. The established 
melanoma cells lines FEMX-I, HHMs and SKMEL-28, and the malignant melanoma cell lines MM 
11, MM 35 and MM 69b were transfected using 4 µg pTracer (control; open bars) or CST6 (closed 
bars) and 10 µl lipofectamine 2000. Total inhibitory activity (IU/ml) against papain was measured 
in the conditioned media. Total inhibitory activity data are given as percent of control (pTracer). 
The transfections were performed by postdoc. Jon Briggs at RUH-HF. 
5.5 Regulation of legumain activity in CST6-transfected cells 
Despite the fact that cystatin M is a secreted protein and legumain is an intracellular protein 
located in lysosomes, it was interesting to investigate if there was any correlation between 
legumain activity and cystatin M in CST6-transfected cells. Thus, legumain activity was 
investigated in cell lysates from HEK 293 and MM 35 cells transfected with CST6, 
respectively. 
5.5.1 Large decrease of legumain activity in CST6-transfected HEK 293 cells 
Measuring legumain activity in cell lysates from CST6-transfected HEK 293 cells showed 
remarkable decrease in activity (46-94 %) when compared to pTracer-transfected cells (n=5) 
(figure 11).  The average decrease of legumain activity in the CST6-transfected cells was 79 
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%. Obvious association between high total inhibitory activity in media from the transfected 
cells (figure 9) and decrease in legumain activity in the cells was observed (table 3). 
 
 
Figure 11: Legumain activity in cell lysates from pTracer- or CST6-transfected HEK 293 cells. 
Cells (2.5-3 x105) were seeded 3 days prior to transfection with 4 µg empty vector (pTracer; control) 
(open bars) or 4 µg CST6 (closed bars) by using 10 µl lipofectamine 2000 for 24 hours. Media and 
cells were harvested 48 hours after start of transfection. Legumain activity was measured 
fluorimetrically by using the substrate Z-Ala-Ala-Asn-NHMec and activity data were adjusted to µg 
total protein. The activity data are given as percent of control (pTracer) (n=5).  
Table 3: Correlation between increase in total inhibitory activity in media and decrease in 
legumain activity of CST6-transfected HEK 293 cells. Cells (2.5-3x105) were seeded 3 days prior 
to transfection with 4 µg empty vector (pTracer) or 4 µg CST6 using 10 µl lipofectamine 2000 for 24 
hours. Media and cells were harvested 48 h after start of transfection. Five independent experiments 
are shown (n.a = not analyzed). 
CST6-transfection  
no. 
% increase in total 
inhibitory activity (IU/ml) 
in cell media 
% decrease in legumain 
activity in corresponding 
cell lysates 
1 36 46 
2 75 80 
3 n.a 81 
4 104 94 
5 n.a 94 
 
5.5.2 Moderate decrease of legumain activity in CST6-transfected melanoma cells 
Legumain activity was also measured in cell lysates from the CST6-transfected established 
melanoma cell lines A-375 and FEMX-I, and the malignant melanoma cell line MM 11. 
There was observed decrease of legumain activity in all the CST6-transfected cell lines 
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(figure 12). The decrease in legumain activity was 41 % in A-375 compared to control 
(pTracer-transfected). In two independent experiments with FEMX-I (A and B), the decrease 
in legumain activity was 13 and 18 %, respectively. Decrease of legumain activity in MM 11 
cells (A and B) was 10 and 20 %, respectively, in two independent experiments (figure 12). 
There was observed a slight correlation between increase in total inhibitory activity in media 
and decrease of legumain activity in CST6-transfected melanoma cells (not shown). 
 
Figure 12: Legumain activity in CST6-transfected melanoma cells. The established melanoma cell 
lines A-375 (n=1) and FEMX-I (n=2; A and B), and the malignant melanoma cell line MM 11 (n=2; 
A and B) were transfected with 4 µg empty vector (pTracer; control; open bars) or CST6 (closed 
bars) using 10 µl lipofectamin 2000.  The transfections were performed by postdoc. Jon Briggs at 
RUH-HF and cell lysates received for enzymatic analysis. Legumain activity was measured 
fluorimetrically and the activity data were adjusted to µg total protein. Activities are given as 
percent of control (pTracer). 
5.6 Regulation of legumain activity after exposure of living cells to 
cystatin M-conditioned media 
Although cystatin M and legumain locate differently in the cells, it was desirable to 
investigate whether addition of cystatin M exogenously had any impact on intracellular 
legumain activity.  For this purpose, HEK 293, THP-1 and PC12 cells were cultured and 
treated by cystatin M-conditioned media from CST6-transfected HEK 293, SKMEL-28 and 
MM 35 cells, respectively. 
5.6.1 Legumain activity decreased in HEK 293 cells  
HEK 293 cells were treated by undiluted cystatin M-conditioned medium from CST6-
transfected HEK 293 cells and legumain activity in the cell lysates was measured. Legumain 
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activity varied and decreased (12-50 %) in all experiments performed (figure 13) with an 
average decrease of legumain activity of 26 %. There was a correlation between high total 
inhibitory activity in the conditioned medium used and decrease in legumain activity (table 
4). 
 
Figure 13: Legumain activity in HEK 293 cells treated with cystatin M-conditioned media from 
CST6-transfected HEK 293 cells. Cells (3x105) were seeded onto 6-well plates 3 days prior to 
treatment with 800 µl control cell media (pTracer; open bars) or cystatin M-conditioned media 
(closed bars). The cells were harvested and lysed 24 hours after treatment with conditioned media. 
The activity data are given as percent of control (pTracer) and adjusted to µg total protein (n=3). 
Table 4: Correlation between increase in total inhibitory activity in conditioned media and 
decrease in HEK 293 cells intracellular activity of legumain. Cells (3x105) were seeded onto 6-well 
plates 3 days prior to treatment with 800 µl control cell media (pTracer) or cystatin M-conditioned 
media. The cells were harvested and lysed 24 hours after treatment with conditioned media. 
Legumain activity, and total inhibitory activity were measured in cell lysates and conditioned media, 
respectively. The data are given as percent of control (empty vector; pTracer). Three independent 
experiments are shown. 
Experiment no. % increase in total inhibitory 
activity (IU/ml) in cystatin M-
conditioned media 
% decrease in legumain 
activity in cell lysates 
1 36 12 
2 75 18 
3 104 50 
 
5.6.2 No regulation of legumain activity in THP-1 cells 
Large increase (approximately 50-fold) in legumain activity was observed when THP-1 cells 
were allowed to grow for ten days after initially 24 hours stimulation with PMA (figure 14). 
PMA-stimulated THP-1 cells were treated with cystatin M-conditioned medium (diluted 1:3 
in THP-1 medium) for 3, 6 and 10 days, respectively. The conditioned media used for this 
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purpose were collected after transfection of HEK 293 cells by CST6- and pTracer-plasmids. 
Only in one of three experiments performed (n=3), a 56 % decrease in legumain activity was 
observed when the cells were treated for 3 days with cystatin M-conditioned medium (with 
36 % increase in total inhibitory activity) compared to control medium (figure 14A). No 
regulation of legumain activity was observed in the other experiments with 75 and 104 % 
increase in total inhibitory activity in conditioned media, respectively (figure 14B and C).  
 
Figure 14: Time-response of legumain activity in PMA-stimulated THP-1 cells treated with 
cystatin M-conditioned media. Cells (5x105) were seeded onto 6-well plates and treated with 40 
ng/ml PMA for 24 hours. After washing (day 0), the cells were allowed to grow for 3, 6, and 10 days. 
Three days before harvesting, the cells were treated either by cystatin M-conditioned media from 
CST6-transfected or control cell media (pTracer), both diluted 1:3 with THP-1 medium (total 1 
ml/well). Controls were treated by THP-1 media only. Data from three independent experiments are 
shown (n=3). Experiments A), B) and C) represent stimulation by cystatin M-conditioned media 
with 36, 75 and 104 % increase in total inhibitory activity, respectively. Legumain activity was 
measured in cell lysates and the activity data were adjusted to µg total protein. 
5.6.3 No regulation of legumain activity in PC12 cells 
PC12 cells were treated by cystatin M-conditioned media from CST6-transfected SKMEL-28 
or MM 35 cells (both diluted 1:1 in PC12 medium) and legumain activity was measured in 
cell lysates. No regulation in enzymatic activity of legumain could be observed upon addition 
of cystatin M-conditioned medium to these cells (figure 15). Increases in total inhibitory 
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activity in the cystatin M-conditioned media used were 39 and 26 % for SKMEL-1 and MM 
35, respectively. 
 
Figure 15: Legumain activity in PC12 cells treated by cystatin M-conditioned media. Cells 
(1.5x105) were seeded onto 6-well plates 4 days prior to addition of cystatin M-conditioned medium 
diluted 1:1 in PC12 medium. Conditioned medium from CST6- (closed bars) or pTracer- (open bars; 
controls) transfected SKMEL-28 or MM 35 cells were used (increase in total inhibitory activity in 
medium from CST6-transfected cells was 39 and 26 %, respectively). After 24 hours stimulation, the 
cells were harvested and lysed. Legumain activity was measured in cell lysates and activity data 
were adjusted to µg total protein. The activity data are given as percent of control (empty vector). 
5.7 Analytical size exclusion chromatography of cell lysates from HEK 
293, THP-1 and PC12 cells 
5.7.1 Molecular weights of  legumain and cathepsin B activities 
Cell lysates from HEK 293 and PC12 cells, as well as PMA-stimulated THP-1 cells (40 
ng/ml, 24 hours) grown for 10 days, were exposed to size exclusion chromatography in order 
to characterize the molecular weights of proteins responsible for the legumain and cathepsin 
B activities in the cells. To find the main legumain and cathepsin B activity fractions, the 
enzyme activities in different fractions were measured (figure 16). Legumain activity varied 
in the cell lines studied and the molecular weight of the fraction (fractions) having highest 
legumain activity was found to be different (figure 16A).  In HEK 293 cells, legumain 
activity eluted in fraction 15 corresponding to a molecular weight of approximately 37 kDa. 
Contrary, in THP-1 cells, fraction 18 (molecular size of approximately 25 kDa) had the 
highest legumain activity. In addition, PC12 cell fraction 16 (approximately 32 kDa) 
possessed the highest legumain activity (figure 16A). 
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Cathepsin B activity in the same fractions was measured as well, in order to investigate the 
correlation with those having highest legumain activity. Very little or no cathepsin B activity 
was observed in HEK 293 cells compared to THP-1 and PC12 cells (figure 16B). Fraction 17 
with a molecular weight of approximately 29 kDa in HEK 293 and THP-1 cells, and fraction 
16 (approximately 32 kDa) in PC12 cells possessed highest cathepsin B activity (figure 16B).  
 
Figure 16:  Molecular weight and enzymatic activities of legumain (A) and cathepsin B (B) in cell 
lysate fractions from size exclusion chromatography. A bulk of HEK 293 and PC12 cells were 
cultured, harvested and lysed. THP-1 cells were stimulated by PMA (40 ng/ml, 24 hours), washed 
and cultured for 10 days. Cell lysates (200 µl) were passed through a Superdex 75 (10 – 30) column 
and fractions of 300 µl were collected. A) Legumain activity in HEK 293, THP-1 and PC12 cells. 
Fractions 12-21 for HEK 293 and THP-1 cells, and PC12 fractions 15-24 were measured. Results 
from one representative experiment are shown (n=2). B) Cathepsin B activity in HEK 293, THP-1 
and PC12 cells. Fractions 10-22 are measured in all cell lines (n=1). Arrows indicate molecular 




5.7.2 Inhibition of legumain activity fractions after size exclusion chromatography 
Since legumain activity fractions in the cell lines studied (HEK 293, THP-1 and PC12 cells) 
had different molecular weights, it was interesting to investigate whether cystatin M or other 
known cysteine protease inhibitors affected legumain activity in these cell fractions. Cystatin 
M-conditioned media from HEK 293 cells transfected with CST6, as well as the cathepsin B-
specific inhibitor CA074 and the cathepsins inhibitor E64 were used to study the inhibitory 
profile of the highest legumain activity fractions of HEK 293, THP-1 and PC12 cells, 
respectively.  
Cystatin M-conditioned medium caused inhibition of legumain activity in all the cell lines 
studied (figure 17A). However, the inhibition varied between the different cell lines. 
Legumain activity fractions from HEK 293 and PC12 showed almost similar inhibitory 
characteristics and were greatly inhibited by cystatin M-conditioned medium. On the 
contrary, the legumain activity fraction of THP-1 cells treated with cystatin M-conditioned 
medium appeared to be less affected. The increase in total inhibitory activity in the cystatin 
M-conditioned medium used to treat all the cell lines was 104 % compared to control 
medium (pTracer-transfected). To inhibit 50 % of legumain activity in PC12, HEK 293 and 
THP-1 cells, 1, 2 and 23 % dilution of cystatin M-conditioned media, respectively, were 
needed. 
In addition, media from HEK 293 cells transfected with empty vector (pTracer; control) or 
CST6 were compared (figure 17B). HEK 293 and PC12 cells were greatly affected by the 
contribution from cystatin M-conditioned medium when compared to control medium. In 
order to inhibit 50 % activity of the legumain fraction from HEK 293 cells, a 5 % dilution of 
cystatin M-conditioned compared to a 47 % dilution of control medium were needed (figure 
17B). In PC12 cells, a 4 % dilution of cystatin M-conditioned compared to a 76 % dilution of 
control medium were needed to inhibit 50 % of legumain activity. Whereas in THP-1 cells, a 
6 % dilution of both cystatin M-conditioned and control medium were needed, this means 








Figure 17: Inhibition of enzyme activity in legumain fractions of HEK 293, THP-1 and PC12 
cells by cystatin M-conditioned media (A) and contribution of cystatin M to the inhibition (B). 
HEK 293 and PC12 cells were cultured, harvested and lysed. THP-1 cells were stimulated by PMA 
(40 ng/ml, 24 hours) washed and cultured for 10 days. Cell lysates (200 µl) were passed through a 
Superdex 75 (10 – 30) column and fractions of 300 µl were collected. Increase in total inhibitory 
activity in the cystatin M-conditioned medium used was 104 %. A) Medium (containing serum) from 
CST6-transfected HEK 293 cells was diluted in serum free media and 17 µl was added to the 
respective legumain fractions (F; 20 µl) in black 96-well plates (n=1). B) Diluted cystatin M-
conditioned and control (empty vector) media were used (n=1). Legumain activity was measured 
using the substrate Z-Ala-Ala-Asn-NHMec. Activity data are given as percent of maximum activity.  
Moreover, legumain activity in the same fractions as above was measured after addition of 
the cathepsin-inhibitors E64 and CA074. Legumain in HEK 293 and PC12 cells were un-
affected by these inhibitors, while legumain in THP-1 cells showed a large decrease in 
activity of 85 and 79 %, respectively, when E64 or CA074 were added (figure 18). 




the difference between activities obtained after additions of control cell media (pTracer) or 
cystatin M-conditioned media, respectively, (figure 17B) at the same dilution (1:4 dilution) 
of media. 
 
Figure 18: Effect of the cysteine protease inhibitors cystatin M, E64 and CA074 on legumain 
activity in HEK293, THP-1 and PC12 cell lysate fractions. HEK 293 and PC12 cells were cultured, 
harvested and lysed. THP-1 cells were stimulated by PMA (40 ng/ml, 24 hours), washed and 
cultured for 10 days. Cell lysates (200 µl) were passed through a superdex 75 (10 – 30) column and 
fractions of 300 µl were collected. Cystatin M-conditioned media (increase in total inhibitory 
activity of 104 %) from CST6-transfected HEK 293 cells was diluted 1:4 in serum free media and 
added to the highest legumain activity fractions. E64 and CA074 (1 µM in dH2O) were added to the 
wells containing 20 µl of fractions in black 96-well plates. Legumain activity was measured by using 
the substrate Z-Ala-Ala-Asn-NHMec. Activity data are given as percent of control (un-treated). 
 53
6. Discussion 
6.1 Establishment of a transfection method 
The major objective of this study was to establish a method in our laboratory for transient 
transfection of rLGMN- or alternatively hCST6-plasmid, encoding rat legumain and human 
cystatin M, respectively. Initially, HEK 293 cells were transfected with rLGMN-plasmid 
using liposomes as the transfection reagent. HEK 293 cells were chosen as the host for 
transfection, since these cells are described as being easily transfectable using liposomes [71] 
and have previously been successfully transfected with human legumain [37, 72]. A number 
of adjustments were made to optimize transfection efficacy with the LGMN-plasmid. The 
most important of these were titration of number of cells, concentration of plasmid and 
amount of liposomes. As transfections were performed in 6-well plates, seeding 5x105 
cells/well one day before transfection or 2.5x105 cells/well three days prior to transfection 
appeared to be most suitable to obtain optimal confluence (80-90 %). Using 20 µl liposomes 
appeared to be toxic to the cells, as cells detached from the culturing flasks. Decreasing 
liposome amount (10 and 5 µl) resulted in less toxicity, especially when 5 µl liposome was 
used. Among other adjustments, transfection was performed in serum and antibiotic 
containing media versus absence of both or one of these.  There might be a possibility that 
antibiotics and contents in serum prevent the DNA plasmid from complex formation with 
liposomes and most protocols are free from both serum and antibiotics. Our cells detached 
easily when cultured without serum, therefore serum was initially preferred during 
transfections. Splitting and culturing in media with serum three days before transfection and 
subsequently transfection and growing in serum and antibiotic free media did not cause any 
detachment of the cells. In this way, the cells were more tightly attached to the culturing 
flasks before transfection process than seeding only one day prior to transfection followed by 
growing in serum free media. Transfection time (3, 6, 9, 24 and 48 hours) with the 
transfection complex (LGMN-plasmid and liposome) was also one of the parameters tested 
under the adjustments. 
To evaluate whether the transfection had caused any increase in legumain expression and/or 
increase in enzymatic activity, immunoblotting and measurements of enzymatic activity were 
performed. Since empty pTarget vector was not available, untreated or liposome treated cells 
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were used as controls. Despite the adjustments made to achieve an optimal transfection 
efficacy, no indications of legumain over-expression could be observed in lysates from the 
LGMN-transfected HEK 293 cells.  However, in two of many comparable experiments, 
when serum was not used during transfection and cells were seeded three days prior to 
transfection, an increase in legumain activity was observed (75 and 20 % compared to 
controls, respectively). These latter incidents, however, were rare observations as similar 
experiments did not confirm these.  
The unsuccessful transfection of HEK 293 cells with the LGMN-plasmid, despite all 
attempts of adjustments, made it necessary to check transfection efficacy of these cells using 
maxFP-Green-plasmid and liposomes. Importantly, it was necessary to test the technical 
aspects under performance of transfections. Fluorescence microscopy verified that the cells 
were efficiently transfected. This confirmed that the transfection method and optimized 
conditions used during the experiments were sufficient for successful transfection. 
Although unsuccessful transfection of the LGMN-plasmid, HEK 293 cells were transfected 
with the hCST6-plasmid (encoding human cystatin M/E, a potent inhibitor of legumain). To 
investigate whether the cells were successfully transfected, the increase in total inhibitory 
activity (IU/ml) against cysteine proteases in media was measured using papain as the target 
enzyme. In all the CST6-transfected cells total inhibitory activity increased but varied 
between experiments. This verified that the transfection method was effective for CST6. 
Since the transfection complex (CST6-plasmid and lipofectamin) was removed and changed 
with fresh media (with or without serum) after 24 hours, the secreted cystatin M in the 
analyzed media was from the last 24 hours before harvesting only. To determine the 
contribution of cystatin M to the total inhibitory activity in media, control cell media 
(pTracer; empty vector) and cystatin M-conditioned media from CST6-transfected cells were 
compared.  In the majority of experiments, both media samples contained 10 % serum which 
contains a wide range of other endogenous substances including cystatins. In two 
experiments, however, media samples did not contain serum and the observed total 
inhibitory activity in control cell media (empty vector; pTracer) was assumed to be the basal 
inhibitory activity of secreted cystatins C, M/E and F to the media. When media from CST6- 
and pTracer-transfected cells were compared, any increase of total inhibitory activity 
observed was due to the contribution from over-expressed cystatin M.  
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Since only the LGMN-plasmid failed to be transfected, possible reasons had to be discussed. 
One of the possible reasons to the failure of LGMN-transfection could be the large size of 
the LGMN-plasmid of approximately 7 kb. Since the CST6-plasmid (approximately 6.7 kb) 
and the maxGFP-Green-Plasmid (4.7 kb) were successfully transfected in HEK 293 cells, the 
hypotheses about impact of insert size became less probable. Based on previous findings, it 
was apparent that the cells were able to internalize the LGMN-plasmid-liposome complex 
and the transfection process was not the reason of failure of legumain over-expression. In a 
corresponding study, on the contrary, HEK 293 cells successfully over-expressed legumain 
when the cells were transfected with mouse legumain-cDNA [43]. In view of the fact that no 
gene sequencing data was provided when the LGMN-plasmid was received, it is likely that 
the LGMN-plasmid contained mutations which prevented successful transcription and 
translation of legumain in HEK 293 cells. This is possible since the construction of the 
LGMN-cDNA was performed by polymerase chain reaction (personal communication: 
Kazumi Ishidoh). Gene sequencing of the received LGMN-plasmid, however, could be 
performed but has not been included due to time limit of this study. 
  
6.2 Molecular weight of active legumain 
It has been shown that legumain in order to be activated must go through two successive 
cleavages of C- and N-terminal prepro-proteins, respectively [46]. Legumain is translated as 
a preproform, transferred through the Golgi apparatus as the proform (56 kDa), and localized 
in lysosomes as the mature active (46 kDa) enzyme [47]. This activation is autocatalytic 
requiring acidic pH [11, 46]. Active legumain in living cells has been shown to possess a 
molecular weight of 36 kDa which is smaller than the active mature enzyme (46 kDa) [46]. 
This last step of activation is probably performed by other lysosomal cysteine proteases. 
When THP-1 cells were treated by L-leucyl-L-leucine methyl ester (Leu-Leu-OMe), which 
makes lysosomal membranes permeable, legumain and cathepsin B activities were completely 
abolished in cell lysates from the cells (personal communication: Eilen Tungland). Leakage in 
lysosomal membrane forced the containing proteases towards the pH neutral environments in 
cytosol where the enzymes are not active. Upon activation by PMA and differentiation 
towards macrophages, THP-1 cells has showen dramatic increase in legumain activity (50-
fold) and mRNA expression (500-fold) [44]. A 32 kDa legumain band appeared by 
immunodetection which was suggested to be consistent with active legumain in THP-1 cells. 
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The antibody used against legumain was self-made by immunizing rabbits with a human 
legumain peptide sequence. 
To characterize different legumain forms (pro- and active) in HEK 293 cells in this study, 
immunoblotting of legumain was performed. Immunoblots of legumain using a commercial 
antibody against legumain (Abcam) in HEK 293 cells revealed three strong bands of 
approximately 57, 45 (double band) and 29 kDa, respectively. For comparison, 
immunoblotting of legumain in HEK 293 cells has earlier shown three strong bands as well, 
but with somewhat different molecular weights [72]. The 29 kDa protein band is assumed to 
be the molecular weight of active legumain, while the other bands are believed to be inactive 
proforms in HEK 293 cells in this study. In the literature, however, higher molecular weights 
(34 kDa, 35 kDa and 36 kDa) have been shown to be responsible for legumain activity [9, 
46, 72]. The molecular weight of purified active pig kidney legumain appeared to be 34 kDa 
[9], while 35 kDa in purified rat and mouse kidney extracts [43, 44]. In HEK 293 cells, the 
active legumain has previously been shown to be a 36 kDa protein [72].  
Furthermore, legumain activity in different elution fractions of HEK 293, THP-1 and PC12 
cell lysates from size exclusion chromatography were measured to determine the molecular 
weight of active legumain in these cells. The amount of cells harvested and lysed for this 
purpose differed between the cell lines studied. Surprisingly, legumain activity was eluted in 
different fractions, with molecular weights of approximately 37, 32 and 25 kDa in HEK 293, 
PC12 and THP-1 cells, respectively. A definite explanation of these different molecular 
weights of active legumain in different cell lines is not known. A possible explanation might 
be that these different molecular weights represent different active forms of legumain which 
are not described yet, all capable of cleaving the specific substrate Z-Ala-Ala-Asn-NHMec. 
Importantly in THP-1 cells, the low molecular weight (25 kDa) active legumain may 
represent a legumain form involved in inflammation and possible the pathophysiology of 
leukemia. This deserves further elucidation. 
Human and pig legumain have been described to have four potential glycosylation sites [9]. 
Several of the plant legumains, as well, are also known to be glycosylated. N-glycosylated 
pig legumain (34 kDa) was converted to a lower molecular weight form (31 kDa) as a result 
of deglycosylation by N-glycosidase F [9, 73]. Different glycosylation reactions with various 
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sugar groups might be another possible explanation to the observed varied molecular weight 
of legumain on Western or size exclusion chromatography in different cells. 
The obtained molecular weight of active legumain in HEK 293 cells after size exclusion 
chromatography (approximately 37 kDa) and immunoblotting (as assumed; approximately 
29 kDa) were different. This may be due to the fact that protein transfer through 
polyacrylamide gels with different concentrations (here 12 %) result in different molecular 
weights. Despite being a well established method for decades, Western blotting is not the 
most precise and reproducible method for assuming molecular weights of proteins.  Since the 
calculated molecular weight of active legumain in HEK 293 cell lysate fractions 
(approximately 37 kDa) was in close agreement with what is described in the literature (36 
kDa) [72], it may represent the active form of legumain in HEK 293 cells. The assumed 
molecular weight of active legumain in THP-1 cell lysate fractions in this study (25 kDa) 
appeared to be consistent with what was reported previously in our laboratory [44].  
6.3 E64 and CA074 inhibit legumain activity in THP-1 cells  
In an attempt to inhibit legumain activity in the cell fractions, different inhibitors were tested. 
Cystatin M (in media from CST6-transfected HEK 293 cells) inhibited legumain activity in 
fractions from all the cell lines studied. This is in consistent with the published literature 
about cystatin M which is described as a potent inhibitor of legumain (Ki 0.0016 nM) [27, 
47, 53, 56]. In HEK 293 and PC12 cell lysate fractions, legumain activity was suppressed 
almost completely, while surprisingly only partially in THP-1 cells. The cathepsin-inhibitors 
E64 and CA074, as expected, did not affect legumain activity in HEK 293 and PC12 cells, 
whereas unexpectedly legumain in THP-1 cells was greatly decreased by these inhibitors. 
Similar surprising finding had previously been observed in individual experiments with 
THP-1 cells and RAW 264.7 cells (rat macrophages) in our research group without further 
investigations (personal communication: Professors Harald T. Johansen and Rigmor 
Solberg). This observation is in conflict with the published literature, where E64 and CA074 
are not shown to influence legumain activity [42, 47]. For the first time such an unusual and 
remarkable phenomenon is being observed for legumain. The actual explanation of this 
observation in THP-1 cells is not identified. One possible explanation is that there might be 
two asparaginyl proteases having almost the same molecular weight, both capable of 
cleaving the specific substrate Z-Ala-Ala-Asn-NHMec. Legumain is probably the cysteine 
 58
protease which is inhibited by cystatin M, and the other unknown legumain-like protease 
may not be affected by cystatin M, but by cathepsin-inhibitors.  
N-glycosylation of asparagine residues has been shown to block attack by legumain at 
otherwise sensitive sites [36, 74]. In addition, N-glycosylation of the asparagine residue 
Asn62 in cystatin F has been assumed to contribute to the reduced activity against legumain 
by altering the shape of the legumain-interacting surface [75]. Given that legumain has 
several potential glycosylation sites [9], it is tempting to speculate that glycosylation is partly 
responsible for the strange inhibition profile for legumain in THP-1 cells. The attached sugar 
groups may modify the conformation of inhibition sites that makes a sufficient interaction 
difficult between inhibitors and the glycosylated sites of legumain. 
In order to further examine the legumain activity fractions in THP-1 cells and to compare 
with a well characterized cysteine protease, cathepsin B activity was measured in the same 
fractions. The molecular weight of the highest cathepsin B activity fraction in THP-1 was 29 
kDa and differed from that of highest legumain activity (25 kDa) in these cells. This 
confirmed that cathepsin B was not represented in the 25 kDa legumain fraction and the 
activity of this fraction was caused by legumain or by a legumain-like protease rather than 
cathepsin B. Similarly, cathepsin B activity was measured in cell lysate fractions of HEK 293 
and PC12 cells. Table 5 summarizes the correlation between molecular weights of legumain 
and cathepsin B activities in HEK 293, THP-1 and PC12 cells and the corresponding cell 
lysate fractions in this study.  
Table 5: Correlation between the molecular weights of legumain and cathepsin B in HEK 293, 
THP-1 and PC12 cells (and the corresponding cell lysate fractions). 
Cell line Legumain 
molecular weight 




HEK 293 37 kDa (15) 29 kDa (17) 
THP-1 25 kDa (18) 29 kDa (17) 
PC12 32 kDa (16) 32 kDa (16) 
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6.4 Interactions between legumain and cystatin M 
As mentioned earlier, cystatins are potent endogenous inhibitors of lysosomal cysteine 
proteases [27, 47, 53, 56]. All functional cystatins are inhibitors of cysteine proteases of the 
papain (C1) family, and some also inhibit enzymes in the legumain (C13) family [14].  The 
secreted type 2 cystatins (C, M/E and F) have been shown to be powerful inhibitors of 
legumain activity, while cytoplasmatic type 1 cystatins (stefins) are not inhibitors of 
legumain [14, 56]. Very recently, it was reported that carboxy terminal extended 
phytocystatins (plant cystatins) are bifunctional inhibitors of papain and legumain [59]. 
Silencing cystatin M/E by a siRNA has been shown to increase both legumain- and cathepsin 
B/L-activities in the cells [23]. 
In this study, legumain activity was observed to be dramatically decreased in CST6-
transfected HEK 293 cells and this decrease was strongly correlated to the potency of the 
total inhibitory activity in the conditioned cell media. For example, 104 % increase of total 
inhibitory activity in media resulted in a 94 % decrease of legumain activity. The same 
correlation but to a lower extent was observed in cell lysates of a number of CST6-
transfected melanoma cell lines. These differences between HEK 293 and melanoma cells 
may due to the nature of these cells, as melanoma cells are cancerous and might have 
distraught balance between proteases and inhibitors among other things. 
Taking in to account that cystatin M and legumain have different cellular locations, 
extracellular and (mainly) intracellular, respectively, this grade of interplay is surprising. 
Whether the secreted cystatin M on its way through the translational and transport cell 
machinery “meets” legumain and inhibits its activity is a possible situation which needs to be 
further explored. Another hypothesis might be the possibility that secreted cystatin M may 
have affinity to cell membranes and in this way appear in cell lysates. This hypothesis 
became more likely by the fact that stimulation of un-treated HEK 293 with cystatin M-
conditioned media caused a moderate inhibition of legumain activity in these cells. 
Interestingly, decrease in legumain activity in these cells was, again, correlated to the 
potency of the total inhibitory activity in the conditioned media used. On the contrary, the 
other studied cell lines (THP-1 and PC12) treated with cystatin M-conditioned media showed 
almost no regulation of legumain activity, regardless potency of the total inhibitory activity 
in the conditioned media used.   
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As mentioned earlier, despite locating mainly in lysosomes, legumain has recently been 
shown to be located extracellularly in the tumour microenvironment, associated with matrix 
and cell surfaces [48]. That makes it likely to suggest another possible explanation of the 
observable facts that over-expression of or exogenously added cystatin M to HEK 293 cells 
reduced legumain activity.  The sub-cellular localization of legumain is not fully elucidated 
and legumain may also exist on the cell surface other than in the tumour microenvironments. 
6.5 Legumain and cystatin M in cancer 
Legumain has been shown to be over-expressed in tumours and has been linked to promotion 
of migration and increased invasiveness [42]. Interestingly legumain over-expression in 
tumour cells was strongly correlated with increased migration and invasiveness in vitro and 
in vivo. Legumain has also been documented to activate pro-MMP2, and thus increase 
degradation of extracellular matrix [37]. Very recently, legumain mRNA expression has been 
shown to be elevated in bovine endometrial tissues during early pregnancy establishment 
[76]. Consequently, local proteolytic activity of legumain has been assumed to play an 
important role in placentation, by regulation of trophoblast (embryo outer layer) invasiveness 
and endometerial remodelling essential for proper placenta formation.  
Recently, legumain has been reported to be over-expressed in tumour associated 
macrophages (TAMs) [49]. TAMs contribute to promotion and proliferation of tumour cells 
by secreting growth and proangiogenic factors as well as metalloproteinases. A full-length 
murine legumain-based DNA vaccine [49] and an oral legumain based minigene vaccine 
[50] against TAMs resulted in suppression of tumour growth, metastasis, and angiogenesis in 
tumours.  
Correspondingly, silencing cystatin M in a metastatic oral cancer cell line increased 
proliferation, invasion and motility of the tumour cells [23]. Interestingly, the activity of 
legumain and cathepsin B and L were increased in the tumour cells. Contrary, over-
expression of cystatin M in a metastatic breast cancer cell line reduced proliferation, invasion 
and motility of the tumours and thus cystatin M has been described as a tumour suppressor 
candidate [22]. Both cystatin M and E64 caused reduction in motility and invasiveness of the 
tumourigenic and metastatic breast cancer cells.  
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To investigate whether CST6-transfection of melanoma cell lines had any effect on migration 
or invasiveness of these cells, pTracer- and CST6-transfectd MM 11 and MM 69b cells has 
been applied to a matrigel (personal communication: postdoc. Jon Briggs; figure 19) which 
resembles the basal membrane around blood vessels. There was observed a 30-40 % 
decreased invasiveness in the CST6-transfected MM 11 cells compared to control (figure 
19A), whereas the CST6-transfected MM 69b cells showed approximately 10 % reduction in 
invasiveness (figure 19B).   
 
   
Figure 19 : Matrigel invasion analysis of the malignant cell lines MM 11 (A) and MM 69b (B) 
following CST6-transfection. Melanoma cells were transfected with 4 µg CST6 or pTracer (control/ 
con). The following day the cells were counted and seeded equally into matrigel plates (matrigel 
dilution 1:40 or 1:60, respectively). Invasion into lower chamber was measured after 72 hours. 
Based on these observations and of legumain activity and inhibition characteristics in the 
same cells in this study, as well as involvements of legumain and cystatin M in cancer, it 
might be concluded that cystatin M is directly and greatly involved in reducing proteolytic 
activity of legumain.  In conclusion, over-expression of cystatin M and thus inhibited activity 
of legumain results in decreased migration and invasiveness of tumour cells.  
Recently, the gene for cystatin M (CST6) was reported to be frequently methylated and hence 
inactivated in a number of breast cancer cell lines when compared to normal breast-tissue 
samples [63]. This was shown to result in inhibition of transcription and silencing of cystatin 
M. Similarly, other reports have shown considerable reduction or loss of cystatin M 
expression in a number of skin cancer cell lines [27]. Premalignant and malignant breast 
cancer cell lines have been reported to express CST6 [27]. Expression of cystatin M in 
malignant cells was demonstrated to abolish several prominent functions such as cell 
proliferation, migration and matrigel invasion. For comparison, 10 of 12 established human 





In an ongoing project of our research group in cooperation with RUH-HF, various melanoma 
cell lines have been screened for expressions of legumain and cystatin M [77]. It has been 
shown a small but not significant tendency of higher legumain activity in cell lysates and a 
corresponding lower total inhibitory activity against cysteine proteases in media from 
melanoma cells compared to non-melanoma cells. On the other hand, cathepsin B activity is 
shown to be significantly higher in melanoma compared to non-melanoma cell lysates and 
there is a positive correlation between cathepsin B activity and expression level.  In addition, 
cystatin C has been observed to be more widely expressed in melanoma cells than cystatin 
M, and cystatin M has not been detected in the established melanoma cell lines. This is in 
agreement with the published literature in other cells [27].  
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7. Conclusions 
The following findings were achieved in this study: 
 A method for over-expression of cystatin M in HEK 293 cells was established. 
 Cystatin M over-expression decreases legumain activity dramatically in the same cell 
and this is strongly correlated with the potency of total inhibitory activity in media.  
 Treating living HEK 293 cells with exogenous cystatin M causes a moderate decrease 
in legumain activity, whereas legumain activity in living PC12 and THP-1 cells are 
not affected. 
 Legumain in THP-1 lysate shows a previously unreported inhibitory profile, as its 
activity is directly decreased by E64 and CA074, respectively, and only partially by 
cystatin M. 
 Legumain in HEK 293 and PC12 cells follows the known inhibitory profile as its 
activity is not affected by either E64 or CA074, but almost completely inhibited by 
cystatin M. 
 The molecular weight of active legumain in HEK 293, THP-1 and PC12 cells was 37, 
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Cell culturing and harvesting  
 
HEK 293 medium  
Dulbecco’s Modified Eagles Medium (DMEM) with 4500 mg/L glucose,  
4 mM L-glutamine and 110 mg/L - sodium pyruvate    500 ml 
            
FBS (heat inactivated, 56°C 30 min) (10 %)      50 ml 
Penicillin (100 U/ml)-streptomycin (100 µg/ml)      5 ml 
 
Autoclaved NaCl 0.9% solution  
NaCl           9 g 
dH2O           1000 ml 
 
Trypsin solution 0.5 % 
Trypsin (10x) 5 %         5 ml 
DMEM (without antibiotics and serum)      ad 50 ml 
 
THP-1 medium: 
RPMI 1640 medium w/2 mM glutamine and  
1.5 g/l Na bicarbonate        500 ml 
Glucose 4.5 g/l (10 %)        22.5 ml 
1 M HEPES          5 ml 
100 mM sodium pyruvate        5 ml 
14.3 M 2-mercaptoethanol        2 µl 
FBS (10 %)           50 ml 
Penicillin (100 U/ml)-streptomycin (100 µg/ml)      5 ml 
250 µg/ml Fungizone (amphotericin B)      5 ml  
 
PC12 medium 
DMEM (Gibco 42430-025)        425 ml 
FBS (10 %)          50 ml 
HS (5 %)          25 ml 
100 mM sodium pyrovate        5 ml 
Penicillin (100 U/ml)-streptomycin (100 µg/ml)         5 ml 
 
PMA solution 40 ng/ml  
PMA (40 nM)          40 µl 
THP-1 medium         960 µl 
 
Lysis buffer (pH 5.8) 
Na3C6H5O7.2H2O         100 mM 
Na2EDTA          1 mM 
n-octyl-β-D-glucopyranoside         1 % (w/v) 
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Solution E 
NaCl           8.5 g 
KCl           500 mg 
KHP2PO4              50 mg 
Na2HPO4          60 mg 
MgSO4.7H2O          200 mg 
HEPES          5 g 
CaCl2.2H2O          150 mg 
dH2O           ad 11 
 
Tryptan blue (0.4 % w/v) 
Tryptan blue          400 mg 
Solution E          ad 100 ml 
Solution is sterile filtered. 
 
1 x PBS 
NaH2PO4.H2O         0.2 g 
Na2HPO4.H2O         1 g 
Na3C6H5O7.2H2O         6 g 
NaCl           8 g 
dH2O           ad 11 
 
 
E. coli culturing and transformation 
Autoclaved LB-medium 
Tryptone           10g 
Yeast extract               5g  
NaCl           10g 
Agar           15g  
dH2O           1 L 
 
SOC medium 
Tryptone          2 % 
Yeast extract          0.5 % 
NaCl           10 mM 
KCl           2.5 mM 
MgCl2           10 mM 
MgSO4          10 mM 
Glucose          20 mM 
Agarose gel electrophoresis 
5 x TBE, Tris-borate-EDTA 
Tris           54 g 
HBr           27.5 g 
EDTA (0.5 M, pH 8.0)        20 ml 





1x TBE buffer solution 
5x TBE buffer solution        200 ml 
dH2O           ad 1000 ml 
 
Agarose gel (1%) 
Agarose          1 g 
1x TBE buffer solution        100 ml 
Ethidium bromide (1 % in water)       5 µl 
 
DNA-loading buffer 
Bromophenol blue         0.25 g 
Xylene cyanol FF         0.25 g 
Ficoll           15 g 
dH2O           ad 100 ml 
 
Protease activity measurements 
Legumain activity measurements: 
 
Legumain assay buffer (pH 5.8) 
C6H8O7 (citric acid)         39.5 mM 
Na2 HPO4          121 mM 
Na2EDTA          1 mM 
CHAPS          0.01 % 
 
Legumain assay buffer with DTT 
DTT (1 mM)          200 µl 
Legumain assay buffer (pH 5.8)       40 ml 
 
Z-Ala-Ala-Asn-NHMec in DMSO (2.5 mM)  
Z-Ala-Ala-Asn-NHMec         13.3 g 
DMSO          9.4 ml 
 
Legumain substrate solution (34 µM) 
Z-Ala-Ala-Asn-NHMec in DMSO (2.5 mM)     200 µl 
Legumain assay buffer (pH 5.8)         14.5 ml 
 
Cathepsin B activity measurements 
 
Cathepsin B assay buffer (pH 5.5) 
CH3COOH 100 %         5.75 ml 
CH3COONa          200 mM 
Na2EDTA          4 mM 
 
Cathepsin B assay buffer with DTT 
DTT (200 mM)         400 µl 
Cathepsin B assay buffer (pH 5.5)        9.6 ml 
dH2O           6.7 ml 
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Cathepsin B substrate solution (68 µM) 
Z-Arg-Arg-NHMec in DMSO (1 mM)      680 µl 
dH2O           ad 10 ml 
 
Total inhibitory activity measurements against papain  
 
Papain assay buffer (pH 6.5) 
NaH2PO4.H2O         14 g 
Na2EDTA          0.4 g 
Brij 35           0.1 g 
 
Papain assay buffer with DTT (pH 6.5) 
Papain assay buffer         30 ml 
DTT (200 mM)         307 µl 
 
Sodium acetate buffer (pH 4.5) 
CH3COOH (acetic acid) (1 M)       1.4 ml 
dH2O           ad 500 ml 
 
Papain dilution (100 000X) 
Dilution 1: 
Papain suspension (18 mg protein/ml)      10 µl 
Sodium acetate buffer (50 mM)       ad 1 ml 
Final dilution (100 000X): 
Dilution 1          10 µl 
Sodium acetate buffer (50 mM)       ad 10 ml 
 
Papain substrate solution (34 µM) 
Z-phe-arg-NHMec in DMSO (1 mM)      680 µl 
dH2O           ad 20 ml 
 
Total protein measurements 
Bio-Rad protein assay colour solution in dH2O (1:5) 
Bio-Rad protein assay dye reagent concentrate     10 ml 
dH2O           40 ml 
 
Western blotting 
Gel buffer (1.5 M Tris-HCl pH 8.8) 
Tris (base)          36 g 
dH2O           ad 200 ml 
 
Stacking gel buffer (0.5 M Tris-HCl pH 6.8) 
Tris (base)          3 g 




SDS (10 %) 
SDS           10 g 
dH2O           ad 100 ml 
 
Ammonium persulphate (APS) 10 % 
APS             5 g 
dH2O           ad 50 ml 
 
Separation gel (12 %) 
dH2O           3.5 ml 
1.5 M Tris-HCl pH 8.8        3.3 ml 
Monomer stock solution         6 ml 
SDS-solution (10 %)         130 µl 
APS (10 %)          65 µl 
TEMED          6.5 µl 
 
Stacking gel (4 %) 
dH2O           6 ml 
0.5 M Tris-HCl pH 6.8        2.5 ml 
Monomer stock solution        1.3 ml 
SDS-solution (10 %)         100 µl 
APS (10 %)          50 µl 
TEMED          10 µl 
 
Electrophoresis buffer (pH 7.5) 
Tris (base)          7.6 g 
Glycine          36 g 
SDS           2.5 g 
dH2O           2.5 L 
 
Blotting buffer (pH 8.3) 
Tris (base)          12 g 
Glycine           58 g 
Metanol          800 ml 
dH2O           ad 41 
 
T-TBS (pH 7.5) 
Tris (base)          2.5 g 
NaCl           11.5 g 
Tween 20          1 ml 
dH2O           ad 21 
 
Blotto (Blocking solution) 
Non-fat dry milk         25 g 




Analytical size exclusion chromatography 
 
Gel filtration buffer (pH 5.0) 
Na3C6H5O7.2H2O         50 mM 
NaCl           150 mM 
Brij 35           0.01 % 
β-mercapto ethanol          2 mM 
Sterile filtered before use. 
 
9.2 Protocols 
Thawing, culturing and splitting HEK 293 cells 
1. Take the Cryo-tube with the frozen HEK 293 cells out from the liquid N2 tank and 
thaw it immediately at 37 oC.  
2. Turn the tube constantly under thawing until a tiny lump of ice remains. 
3. Transfer the cell suspension (1 ml) to a 75 cm2 Corning flask and add 11 ml growth 
medium. 
4. Incubate at 37 oC and 5 % CO2 for 24 hour. 
5. Aspirate old medium and add 12 ml fresh growth medium. Incubate (at 37 o C and 0.5 
% CO2) until splitting (80-90 % confluence, approximately every 4th day). 
6. Aspirate medium and wash once in 10 ml sterile 0.9 % NaCl or DMEM without 
serum. 
7. Add 2 ml trypsin-EDTA (0.5 % in DMEM without serum) to the 75 cm3 flasks and let 
stay for 1 minute at room temperature. Bring the cells into suspension by tapping the 
side wall of the plate. Check in microscope. 
8. Add 15 ml medium (with FBS to inactivate trypsin). 
9. Transfer to a 15 ml tube and sentrifuge (800 rpm, 5 minutes). 
10. Aspirate trypsin/medium 
11. Resuspend in fresh medium (5-10 ml). 
12. Count cells for experiments. 
13. Seed the cells onto six-well plates and/or 75 cm3 flasks as wanted.  
14. Incubate at 37 o C and 0.5 % CO2.  
 
Thawing, culturing and splitting THP-1 cells 
1. Take the Cryo-tube with the frozen THP-1 cells out from the liquid N2 tank and thaw 
it immediately at 37 oC.  
2. Turn the tube constantly under thawing until a tiny lump of ice remains. 
3. Transfer the cell suspension (1 ml) to a 75 cm2 Corning flask and add 9 ml growth 
medium. 
4. Incubate at 37 oC and 5 % CO2 for 24 hours. 
5. Centrifuge the cells at 800 rpm for 5 minutes and aspirate medium. 
6. Wash the cell pellet with RPMI without additives and resuspend in 8 ml RPMI 
medium. 
7. Count the cells.  
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8. Transfer a volume corresponding to 1 million cells/ml (usually 1 ml) to a new 75 cm2 
Corning flask and add 9 ml growth medium and incubate for 72 hours at 37 oC and 5 
% CO2.  
9. After 72 hours, new medium should be added (10 ml). 
10. Split the cells whenever the concentration of the cells in the flask is about 1 
million/ml (approximately once weekly) taking 1 million cells/ml and adding 9 ml 
RPMI medium.  
 
Thawing, culturing and splitting PC12 cells 
1. Add 10 ml medium in a 15 ml tube. 
2. Put another 15 ml tube on ice. 
3. Thaw cells at 37 °C until little ice left. 
4. Transfer cells to the empty tube on ice. 
5. Add medium over 2-3 minutes, resuspend. 
6. Spinn cells (800 rpm, 5 minutes), resuspend in fresh medium. 
7. Transfer to a culture flask. 
8. Split (when 80-90 % confluence, approximately every 3-4th day): Aspirate old 
medium. 
9. Hit flask to dislodge cells.  
10. Add 5-10 ml fresh medium.  
11. Break clusters by pipetting (x 5-10). Check in microscope. 
12. Add 1 ml to a new flask containing 11 ml medium. 
13. Remove old and add fresh medium every second day. 
Cell freezing  
HEK 293 cells 
1. Treat cells with 2 ml trypsin-EDTA (to 75 cm3 flasks) and let stay for 1 minute at 
room temp. Check in microscope. 
2. Add 15 ml medium (with FBS to inactivate trypsin). 
3. Transfer to a 15 ml tube and centrifuge (800 rpm, 5 minutes). 
4. Aspirate trypsin/medium. 
5. Make 10 % DMSO in DMEM (100 µl DMSO + 900 µl DMEM including 
FBS/antibiotics) on ice. 
6. Resuspend cells in 10 % DMSO in DMEM (cold) to a final cell concentration of 2 
millions/ml. 
7. Transfer 1 ml per labelled Cryo-tube. 




1. Count cells and transfer to a 15 ml tube. 
2. Centrifuge (800 rpm, 5 minutes). 
3. Aspirate media  
4. Make 5 % DMSO in media (0.5 ml DMSO + 9.5 ml growth media) on ice. 
5. Resuspend in 5 % DMSO in growth media to a final volume of 1 million/ml. 
6. Transfer 1 ml per labelled Cryo-tube. 
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7. Set 5-10 minutes on ice, 2 hours at -70 °C (dry ice), before transferring to liquid 
nitrogen for long term storage. 
 
PC12 cells 
1. Transfer cell suspension to a 15 ml tube and centrifuge (800 rpm, 5 minutes). 
2. Resuspend cells in 1 ml cold medium (10 % FBS).  
3. Make 20 % DMSO in FBS (200 µl DMSO + 800 µl FBS) on ice. 
4. Add gently 20 % DMSO-solution to the cells, resuspend a few times (Pasteur) over 2-
3 minutes on ice. 
5. Transfer 1 ml per labelled Cryo-tube (approx 3-4 mill cells/tube). 
6. Set 10 minutes on ice, 30 minutes at -70 °C (dry ice), before transferring to liquid 
nitrogen for long term storage. 
Transformation of E. coli with plasmids 
1. Thaw one 50 µl vial of One Shot® cells (chemically competent E. coli) (Invitrogen) on 
ice for 10 minutes.  
2. Add plasmid DNA (1-2 µg), pipette gently to mix.  
3. Let stay for 30 minutes on ice.  
4. Incubate cells for 35 seconds at 42oC (heat shock). 
5. Incubate cells on ice for 2 min.  
6. Add 1 ml SOC-medium.  
7. Incubate for 1 hour at 37oC on shaker (100 rpm).  
8. Centrifuge the cells at the lowest possible rpm for 3 minutes. 
9. Aspirate 900 µl of the supernatant, and re-suspend the cells using the remaining 100 
µl of the supernatant. 
10. Spread 100 µl onto an agar plate made with ampicillin.  
11. Grow overnight at 37 °C.  
12. Pick up only one bacterial colony from the agar plate and transfer to 3 ml liquid LB-
medium and 3 µl ampicillin (50 mg/ml). Incubate at 37 oC under moderate agitation 
for 24 hours. 
13. Prepare glycerol stocks in Cryo-tubes by gently mixing 800 µl bacterial suspension 
and 200 µl glycerol. Freeze at -70 oC. 
14. Centrifuge the remaining cells (from stage 1) at 5000 g and 5 oC for 20 minutes and 
carefully remove all traces of medium. Then follow the protocol for QIAprep spin 
miniprep kit. 
 
Isolation and purification of plasmids (Mini-prep) 
QIAprep spin miniprep kit (QIAGEN): 
1.   Resuspend the pelleted bacterial cells in 250 µl Buffer P1 (kept at 4 °C) and transfer 
to an eppendorf tube. Ensure that RNase A has been added to Buffer P1. No cell 
clumps should be visible after resuspension of the pellet. 
2.   Add 250 µl Buffer P2 and mix gently by inverting the tube 4–6 times. Do not 
vortex, as this will result in shearing of genomic DNA. If necessary, continue 
inverting the tube until the solution becomes viscous and slightly clear, but do not 
allow the lysis reaction to proceed for more than 5 minutes. 
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3.   Add 350 µl Buffer N3 and invert the tube immediately but gently and thoroughly 4–
6 times. The solution should become cloudy. 
4.   Centrifuge for 10 minutes at 13 000 rpm (~17,900 x g) in a microcentrifuge. 
A compact white pellet will form. 
5.   Apply the supernatants from step 4 to the QIAprep spin. 
6.   Centrifuge at 13 000 rpm for 30–60 seconds. Discard the flow-through. Spinning for 
60 seconds produces good results. 
7.   (Optional): Wash the QIAprep spin column by adding 0.5 ml Buffer PB and 
centrifuging for 30–60 seconds. Discard the flow-through. 
8.   Wash the QIAprep spin column by adding 0.75 ml Buffer PE and centrifuging at 
13 000 rpm for 30–60 seconds. Spinning for 60 seconds produces good results. 
9.   Discard the flow-through, and centrifuge for an additional 1 minute to remove 
residual wash buffer. 
10. Place the QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute DNA, 
add 50 µl Buffer EB (10 mM Tris-HCl, pH 8.5) or water to the middle of each 
QIAprep spin column, let stand for 1 minute, and centrifuge for 1 minute. 
Isolation and purification of plasmids (Maxi-prep) 
Culturing of bacteria transformed with plasmid 
1. From the E. coli stock in glycerol in the freezer (-70 oC), scrape a little amount of the 
bacterial stock by a scoop and seed onto an agar plate (with ampicillin) and let the 
bacteria grow overnight at 37 oC. 
2. Pick up one bacterial colony and suspend in 3 ml liquid LB-medium, before adding 3 
µl ampicillin (50 mg/ml). Incubate at 37 oC under moderate agitation for 
approximately 5 hours. 
3. Transfer 100 µl of the bacterial suspension to a larger container with 180 ml LB-
medium before adding 180 µl ampicillin (50 mg/ml). Incubate at 37 oC under 
agitation overnight. 
4. Transfer to a centrifuge tube and follow the JETSTAR maxiprep protocol for plasmid 
purification from E. coli.   
 
JETSTAR plasmid kit (maxiprep) 
1. Centrifuge the bacterial suspension at 5000 g and 5 oC for 20 minutes and remove 
carefully all traces of medium. 
2. Reconstitute the bacterial pellet by adding 10 ml solution E1. Continue until a 
homogenous suspension is formed. 
3. Cell lysis occurs upon the addition of 10 ml solution E2. Mix gently by inverting until 
a homogenous cell lyate is formed. 
4. Add 10 ml solution E3, in order to neutralize the lysate, mix immediately by multiple 
inverting until homogeneity is achieved. Transfer the mixture to a smaller centrifuge 
tube and centrifuge the mixture at 12000 g and 4 oC for 10 minutes. 
5. While centrifugation, equilibrate the maxiprep column by applying 30 ml solution E4 
to the column. Allow the column to empty by gravity flow. 
6. The supernatant from step 4 is then applied to the column and allowed to run by 
gravity flow. 
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7. Wash the column once by adding 60 ml solution E5 and allow the column to empty 
by gravity flow. 
8. Elute the plasmid using 15 ml solution E6. COLLECT this solution! 
9. Precipitate the DNA with 10.5 ml isopropanol and centrifuge at 4 oC and 12000 g for 
30 minutes. Wash the plasmid with 10 ml 70 % ethanol and air-dry the pellet for 15-
30 minutes. The dried pellet is then re-dissolved in 500 µl of a suitable buffer (i.e. 10 
mM Tris-HCl pH 8, TE buffer or sterile water). Transfer the plasmid solution to a 
microcentrifuge tube and store at 4 oC. 
Agarose gel electrophoresis 
1. Prepare a 1 % agarose gel by adding 100 ml buffer (1x TBE) to 1 g agarose.  
2. Boil the solution in a microwave oven in order to dissolve the agarose (avoid 
superheating of the gel).  
3. Add 5 µl ethidium bromide (1 %) while the gel solution is still warm. 
4. Place a comb and pour the warm agarose (approximately 50 oC) into a form and let 
the gel stiffen at room temperature for 40 minutes.  
5. Remove the comb before the addition of a sufficient amount of 1x TBE.  
6. Load the samples into the wells. 
7. Apply the electrical current (100 V for 1-2 hours).  
8. Examine the gel by UV-light and take a photo.  
 
Transient transfection of HEK 293 cells with LGMN- and CST6-plasmids 
1. Seed 0.5 x106 cells/well one day before transfection (or 2.5-3 x106 cells/well three 
days prior to transfection) onto six-well plates. Up to 1 or 2 ml growth medium/well 
(for LGMN*- and CST6- transfection, respectively). 
2. Prepare the following solutions for the transfection process per well: 
A) Plasmids (1-20 µg/ml) diluted in DMEM +/- serum and antibiotics (for CST6: 
only DMEM -/- serum and antibiotics).  
B) Lipofectamin 2000 (5-20 µl/ml) diluted in DMEM +/- serum and antibiotics (for 
CST6: only DMEM -/- serum and antibiotics). 
3. Combine solutions A and B and mix gently. Incubate at room temperature for 30 
minutes. 
4. Remove media from the wells and overlay 1-2 ml Lipid-DNA solution (A+B) to the 
cells.  
5. Incubate for 24-48 hours. 
 
*Check table 2 for adjustments. 
Measuring proteolytic activity of legumain and cathepsin B 
1. Add 20 µl of samples or blank (lysis buffer) to a black 96-well microplate, each in 
triplicate. Temperature should be adjusted at 30 oC on the Wallac Victor. 
2. For legumain: 
A) Prepare a solution containing 100 µl DTT (200 mM) and 20 ml legumain 
assay buffer. This solution should be freshly made before every assay. 
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B) Prepare legumain substrate solution by combining 200 µl Z-Ala-Ala-Asn-
NHMec (2.5 mM in DMSO) and 14.5 ml legumain assay buffer. 
For cathepsin B: 
A) Prepare a solution containing 400 µl DTT (200 mM) and 10 ml cathepsin 
B assay buffer. Aspirate 1 ml and add 6 ml dH2O. This solution should be 
freshly made before every assay. 
B) Prepare cathepsin B substrate solution by combining 680 µl Z-Arg-Arg-
NHMec (1.0 mM in DMSO) and 10 ml dH2O. 
3. Insert the buffer and substrate tubes in the Wallac Victor’s injector positions 1 and 2, 
respectively. 
4. On Victor, click/mark for the injectors, fill and apply respectively. 
5. From the workout command, chose the proper protocol for the assay. 
6. Place the 96-wells microplate in the instrument and start the assay. 
A) Each well will be added 100 µl assay buffer. 
B) Immediately before measurements, each well will be added 50 µl substrate 
solution. 
7. Kinetic will be measured in ∆F/s. 
Measuring total inhibitory activity against papain 
1. Boil collected media samples (100 oC, 5 minutes) and centrifuge at 10000 g and 4 oC 
for 5 minutes. Transfer the supernatants to new eppendorf tubes. 
2. Make different dilutions of the samples using serum-free medium. For example 80 %, 
70 %, 60 %, 50 % etc. 
3. Prepare following solutions: 
A) Papain solution: in an eppendorf tube, mix 10 µl of a papain suspension 
(18 mg protein/ml) and 990 µl sodium acetate buffer (1000 X), and 
transfer 10 µl to a tube containing 9990 µl sodium acetate (100 000 X). 
B) Papain peptide substrate solution (34 µM): Mix 680 µl Z-phenyl-arginin-
NHMec and distillated water up to 20 ml.  
C) Activated papain assay buffer: Add 307 µl of 200 mM DTT to 30 ml 
papain assay buffer.  
4. To the first 3 wells (blank) add 20 µl sodium acetate buffer and 17 µl papain assay 
buffer (without DTT). 
5. To the papain control wells (usually 6 wells) add 20 µl papain solution and 17 µl 
serum-free medium. 
6. To sample wells, add 20 µl papain solution and 17 µl of the different prepared 
dilutions of the media samples. 
7. Chose the right protocol (from the software; workout) for the measurement of 
inhibitory activity and make adjustments if necessary. Keep the temperature at 37 oC. 
A) Every well (not the blanks) is added 83 µl of activated papain assay buffer 
(by the auto-injector), and the plate is then shaken in 10 seconds and 
incubated for 10 minutes at 37 oC. 
B) The wells are added 50 µl of the peptide substrate solution (34 µM Z-
phenyl-arginin-NHMec) to a final concentration of 10 µM and the final 
volume is 170 µl. 
8.  The fluorescence is immediately measured and repeated 10 times with an interval of 
1 minute and a shaking period of 3 seconds in-between each measurement. 
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Fluorescence measurements are performed at 355 nm excitation and 460 nm 
emission. 
 
Measuring total protein concentration (standard version): 
1. Prepare the colour reagent by mixing 1 part of Bio-Rad Protein Assay Dye Reagent 
Concentrate with 4 parts of distillated water. Sterile filtrate (0.2 µm) the solution.  
2. To a transparent 96-well microplate (Costar), add 10 µl of standard solutions of 
serum albumin (0, 50, 100, 150, 200, 250, 300 µg/ml), which is diluted in lysis 
buffer, in parallels. 
3. Add 10 µl of the samples to the microplate in parallels as well. 
4. Apply 200 µl of the prepared colour reagent to each well. 
5. Incubate the plate at room temperature for 5 minutes, before measuring the 




 Make T-TBS and the blocking solutions as described earlier. 
B) Sample preparation (TCA precipitation): (The samples are kept on ice during the whole 
process) 
1. Add 1.2 ml sample to an eppendorf tube. 
2. Add 120 µl TCA (100 %) and mix well (vortex). Incubate on ice for 30 minutes 
and centrifuge at 10000 g and 4 oC for 5 minutes. Remove the supernatant. 
3. Resuspend the pellet with 1.2 ml TCA (1 %) and mix well by vortexing (can be 
difficult to resuspend). Centrifuge at 10000 g and 4 oC for 5 minutes and remove 
the supernatant. 
4. Add 30 µl 0.1 M NaOH and mix well (vortex). 
5. Add 10 µl 4X sample-buffer. 
6. Add 10 % β-mercapto ethanol and 5 % bromophenol blue calculated as percent of 
the final volume of the samples in order to have the same concentration of proteins 
in the samples. 
7. Add 1X sample-buffer. The amount is estimated based on the final volume of the 
samples.  
8. Boil the samples (100 oC) for 5 minutes. 
C) Polyacrylamide gels: 
1. Put together different pieces of gel pouring equipment and make sure that the 
system is tight. 
2. Prepare the 12 % separation gel as described under solutions. APS and TEMED are 
added at the end. 
3. Mix well, pour the gel and add isobutanol (200 µl) to straighten the surface of the 
gel and remove air bubbles. 
4. Let stiffen for approximately 45 minutes. 
5. Remove isobutanol and wash with dH2O. 
6. Make the 4 % stacking gel as described under solutions. Pour it on the separation 
gel and place a comb. Add more stacking gel solution until the form is filled. 
7. Let the gel stiffen for approximately 45 minutes. 
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8. Separate the gel pouring form carefully from each other and wash with dH2O. Use 
the gel directly or pack in wet papers and keep at 4 oC until analysis. 
D) Gel electrophoresis: 
1. Set up the gel in an electrophoresis tank and fill with electrophoresis buffer (pH 
7.5).  
2. Apply samples (10-20 µg) and precision standard (2.5 µl) to the gel.  
3. Connect water (to cool down the system) and start electrophoresis at 200 V for 
approximately 1 hour and 20 minutes or stop when bands reach the lowest part of 
the gel. 
E) Membrane transfer (Western blotting): 
1. Cut a nitrocellulose membrane and filter papers in suitable sizes and soak in 
blotting buffer (pH 8.3) for 10 minutes. 
2. Prepare a sandwich from gels, membranes and filter papers on the blotting 
apparatus with the following layers in order from cathode (-) to anode (+):  1) filter 
paper (3 sheets) soaked in transfer buffer, 2) gel, 3) membrane, 4) filter paper (3 
sheets) soaked in blotting buffer, 5) Mylar mask which points the electrical current 
towards the sandwich only. Add blotting buffer between each layer. 
3. Subject the sandwich to an electrical current (64 mA for two gels and 32 mA for 
one gel) for 45-60 minutes. 
4. Membranes are coloured in Ponceau S-solution for 1 minute, wash and make a 
copy. 
F) Addition of antibodies  
1. Put membranes in dH2O for few minutes, followed by 10 minutes in T-TBS. 
2. Block membranes with blocking solution (Blotto) for 60 minutes at room 
temperature. 
3. Remove Blotto and add primary antibody (in Blotto). Ten ml Blotto is used for 
each membrane. Dilution of primary antibody depends on antibody type. 
4. Incubate at 4 oC overnight under slight agitation. 
5. Wash membranes with Blotto (3 x 10 minutes), under slight agitation, at room 
temperature. 
6. Add secondary antibody (-HRP) in Blotto (10 ml).  Dilution of secondary antibody 
depends on type of antibody. 
7. Remove secondary antibody and wash with Blotto (3 x 10 minutes), under slight 
agitation, at room temperature. 
8. Wash membranes with T-TBS (2-3 x 10 minutes), under slight agitation, at room 
temperature. 
G) Evoking immunoreactive bands 
1. Incubate membranes in enhanced chemiluminescense (ECL) solution (Amersham) 
for 1 minute. Mix reagents 1:1 (as recommended by the manufacturer). 
2. Pack membranes in a plastic transparent film.  
3. Turn off the light and put membranes together with an x-ray film in a cartridge. 
4. Evoke immunoreactive bands (for 5, 15 and 60 minutes).   
5. Incubate in a developer solution for 30 seconds, wash in water and incubate in a 
fixer solution for 5 minutes. Let films air-dry. 
6. Quantify bands by the software GeneTools (Syngene). 
 
 
